


# Journal Pre-proof

Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Nitin Bharat Charbe, Nikhil D. Amnerkar, B. Ramesh, Murtaza M. Tambuwala, Hamid A. Bakshi, Alaa A.A. Aljabali, Saurabh C. Khadse, Rajendran Satheeshkumar, Saurabh Satija, Meenu Metha, Dinesh Kumar Chellappan, Garima Shrivastava, Gaurav Gupta, Poonam Negi, Kamal Dua, Flavia C. Zacconi



PII: S2211-3835(20)30756-5

DOI: <https://doi.org/10.1016/j.apsb.2020.10.005>

Reference: APSB 911

To appear in: *Acta Pharmaceutica Sinica B*

Received Date: 12 May 2020


Revised Date: 24 June 2020

Accepted Date: 8 October 2020

Please cite this article as: Charbe NB, Amnerkar ND, Ramesh B, Tambuwala MM, Bakshi HA, Aljabali AAA, Khadse SC, Satheeshkumar R, Satija S, Metha M, Chellappan DK, Shrivastava G, Gupta G, Negi P, Dua K, Zacconi FC, Small interfering RNA for cancer treatment: overcoming hurdles in delivery, *Acta Pharmaceutica Sinica B*, <https://doi.org/10.1016/j.apsb.2020.10.005>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. All rights reserved.



The latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells were highlighted. It also provides the necessary information about siRNA development and its mechanism of action.

## REVIEW

### Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Nitin Bharat Charbe<sup>a,b,\*</sup>, Nikhil D. Amnerkar<sup>c</sup>, B. Ramesh<sup>b</sup>, Murtaza M. Tambuwala<sup>d</sup>, Hamid A. Bakshi<sup>d</sup>, Alaa A. A. Aljabali<sup>e</sup>, Saurabh C. Khadse<sup>f</sup>, Rajendran Satheeshkumar<sup>a</sup>, Saurabh Satija<sup>g,h</sup>, Meenu Metha<sup>g,h</sup>, Dinesh Kumar Chellappan<sup>i</sup>, Garima Shrivastava<sup>j</sup>, Gaurav Gupta<sup>k</sup>, Poonam Negi<sup>l</sup>, Kamal Dua<sup>g,l,m</sup>, Flavia C. Zacconi<sup>a,n,\*</sup>

<sup>a</sup>*Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile*

<sup>b</sup>*Sri Adichunchunagiri College of Pharmacy, Sri Adichunchunagiri University, BG Nagar, Karnataka 571418, India*

<sup>c</sup>*Adv V. R. Manohar Institute of Diploma in Pharmacy, Nagpur, Maharashtra 441110, India*

<sup>d</sup>*School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK*

<sup>e</sup>*Faculty of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 21163, Jordan*

<sup>f</sup>*Department of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education and Research, Dist. Dhule, Maharashtra 425 405, India*

<sup>g</sup>*Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia*

<sup>h</sup>*School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India*

<sup>i</sup>*Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia*

<sup>j</sup>*Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Delhi, New Delhi 110016, India*

<sup>k</sup>*School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur 302017, India*

<sup>1</sup>*School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan, India 173229, India*

<sup>m</sup>*Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) and School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW 2308, Australia*

<sup>n</sup>*Institute for Biological and Medical Engineering, Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 4860, Chile*

\*Corresponding authors.

E-mail addresses: fzacconi@uc.cl (Flavia Zacconi), Nitinunimi@gmail.com (Nitin Charbe).

**Abbreviations:** APOB, apolipoprotein B; AQP-5, aquaporin-5; Atufect01,  $\beta$ -L-arginyl-2,3-L-diaminopropionic acid-*N*-palmitoyl-*N*-oleyl-amide trihydrochloride; AuNPs, gold nanoparticles; AZEMA, azidoethyl methacrylate; BMA, butyl methacrylate; B-PEI, branched polyethylenimine; *CFTR*, cystic fibrosis transmembrane conductance regulator gene; CHEMS, cholesteryl hemisuccinate; CHOL, cholesterol; CMC, critical micelles concentration; DC-Chol,  $3\beta$ -[*N*-(*N*',*N*'-dimethylaminoethane)carbamoyl]cholesterol; DMAEMA, 2-dimethylaminoethyl methacrylate; DNA, deoxyribonucleic acid; DOPC, dioleoylphosphatidyl choline; DOPE, dioleoylphosphatidyl ethanolamine; DOTAP, *N*-[1-(2,3-dioleoyloxy)propyl]-*N,N,N*-trimethylammonium methyl-sulfate; *DOTMA*, *N*-[1-(2,3-dioleoyloxy)propyl]-*N,N,N*-trimethylammonium chloride; DOX, doxorubicin; DSGLA, *N,N*-dis-tearyl-*N*-methyl-*N*-2[*N*'-(*N*2-guanidino-L-lysiny)] aminoethylammonium chloride; DSPC, 1,2-distearoyl-*sn*-glycero-3-phosphocholine; DSPE, 1,2-distearoyl-*sn*-glycero-3-phosphorylethanolamine; DSPE-MPEG: 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine-*N*-[methoxy(polyethylene glycol)-2000] (ammonium salt); DSPE-PEG-Mal: 1,2-distearoyl-*sn*-glycero-3-phosphoethanolamine-*N*-[maleimide(polyethylene glycol)-2000] (mmmonium salt); EPR: enhanced permeability and retention; Galnac, *N*-acetylgalactosamine; HIF-1 $\alpha$ , hypoxia-inducible factor-1 $\alpha$ ; KSP, kinesin spindle protein; LDI, lysine ethyl ester diisocyanate; LPD/LPH, lipid-protamine-DNA/hyaluronic acid; MDR, multiple drug resistance; MiRNA, micro RNA; MPEG, methoxypoly(ethylene glycol); MPEG-PCL, methoxy polyethylene glycol-polycaprolactone; mRNA, messenger RNA; MTX, methotrexate; NIR, near-infrared; NP, nanoparticle; NRP-1, neuropilin-1; PAA, 2-propylacrylic acid; PAH-*b*-PDMAPMA-*b*-PAH, poly(acrylylhydrazine)-*block*-poly(3-dimethylaminopropyl methacrylamide)-*block*-poly(acrylylhydrazine); PCL, poly(E-caprolactone); PCL-PEG, polycaprolactone-polyethyleneglycol; PCL-PEG-PHIS, poly(E-caprolactone)-polyethyleneglycol-poly(L-histidine); PCL-PEI,

polycaprolactone-polyethylenimine; PDMA, poly(*N,N*-dimethylacrylamide); PDO, 1,3-propanediol; PEG-*b*-PDMAEMA-*b*-Ppy, poly(ethylene glycol)-*block*-poly(2-dimethylaminoethyl methacrylate)-*block* poly(pyrenylmethyl methacrylate); PEG-*b*-PLL, poly(ethylene glycol)-*block*-poly(L-lysine); PEI, polyethylenimine; PEO-*b*-P(DEA-Stat-MEMA, poly(ethylene oxide)-*block*-poly(2-(diethylamino)ethyl methacrylate)-stat-poly(methoxyethyl methacrylate); PEO-*b*-PCL, poly(ethylene oxide)-*block*-poly( $\epsilon$ -caprolactone); PE-PCL-*b*-PNIPAM, poly(*N*-isopropyl acrylamide), pentaerythritol polycaprolactone-*block*-poly(*N*-isopropylacrylamide); PE-PCL-*b*-PNVCL, pentaerythritol polycaprolactone-*block*-poly(*N*-vinylcaprolactam); PiRNA, piwi-interacting RNA; PLA, poly-L-arginine; PLGA, poly lactic-*co*-glycolic acid; PLk-1, polo-like kinase 1; PLL, poly-L-lysine; PPES-*b*-PEO-*b*-PPES, poly(4-(phenylethynyl)styrene)-*block*-PEO-*block*-poly(4-(phenylethynyl)styrene); PTX, paclitaxel; RES, reticuloendothelial system; RGD, Arg-Gly-Asp peptide; RNA, ribonucleic acid; RNAi, RNA interference; RISC, RNA-induced silencing complex; RNase III, ribonuclease III enzyme; S-Au, thio-gold; SEM, scanning electron microscope; SiRNA, short interfering rNA; SNALP, stable nucleic acid-lipid particles; TCC, transitional cell carcinoma; TEM, transmission electron microscopy; Tf, transferrin; Trka, tropomyosin receptor kinase A; USPIO, ultra-small superparamagnetic iron oxide nanoparticles; UV, ultraviolet; VEGF, vascular endothelial growth factor; ZEBOV, *Zaire ebola virus*

**Abstract** In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.

**KEY WORDS** Small interfering RNA (siRNA); Nanomedicine; Liposomes; Micelles; Cancer; Polymer

## 1. Introduction

In the recent past, one of the most transformed fields of science is molecular biology. This transformation has occurred on several fronts; one of them is the small non-coding RNA, which

regulates gene expression. Based on their biological roles and structures, small non-coding RNAs are classified into three main categories: miRNAs, siRNAs, and piRNAs<sup>1</sup>.

siRNA, also known as short interfering RNA, is a type of non-coding double-stranded RNA of 20–23 nucleotide base pairs in length. As the name suggests, it acts by interfering with the expression of the specific gene having a complementary sequence. The siRNA is similar to microRNA in terms of functions, except that the microRNA can regulate the expression of hundreds of genes *via* imperfect base pairing. In contrast, siRNA binds more specifically to the single gene at a particular location<sup>1</sup>. Although siRNA and miRNA are noncoding RNAs that share a common role in gene silencing and regulation, their mode of action and clinical potential are different. One of the significant differences between these two is that the miRNA has multiple targets, whereas siRNA has only one mRNA target. The clinical application of these two is thus, different from each other. The therapeutic potential of siRNAs and miRNAs is verified in the treatment of cancer and certain other diseases and infections<sup>2</sup>.

SiRNA is produced from the long dsRNAs and small hairpin RNAs with the help of enzyme dicer. It prevents the process of translation by degrading mRNA. This function of the siRNA is seen as one of the most critical therapeutic tools for the treatment of various genetic disorders, including cancer.

## 2. SiRNA production and interference mechanism

Sense and antisense strands of siRNA are transcribed from the same loci of the DNA template. This is the endogenous source of the small RNA molecules<sup>1</sup>. RNA molecules can also be introduced exogenously, which has already become a vital tool in laboratory medicine and research. Due to transcription from the same loci of DNA, RNA strands have the complementary sequence, which leads to the formation of the double-strand RNA molecules. Once formed, double-strand RNA, along with the associated proteins, moves in the cytosol through the nuclear pores where it cleaved to create the single strand siRNA. The enzyme responsible for the cleavage is the dicer, an RNase III type enzyme (RNA specific endonuclease). This cleavage leads to the overhang of two nucleotides at the 3' ends and monophosphate at 5' ends. siRNA thus formed, in association with ARGONAUTE and other proteins, create the silencing effector complex, which binds to the target mRNA *via* Watson–Crick base pairing. In most cases, silencing is the direct effect of this interaction. In short, after cleavage by dicer, the small RNA molecules of around 21 nucleotides are loaded on to the multiprotein complex (ribonucleoprotein), called RISC<sup>3</sup>. The loading efficiency of different siRNAs into the RISC varies considerably. Several studies revealed that one of the key features which affect the loading efficacy is the structure of RNA.

Due to the variation of the loading efficacy, potency of the downstream effect of siRNA on gene silencing also varies.  $\alpha$ -form helix is supposed to have the perfect and stable fit than the  $\beta$ -form helix to trigger the RNA interference<sup>4</sup>. In the case of the exogenous pathway (externally introduced siRNA), siRNA of the same length could directly load into the RISC without prior processing by the dicer enzyme<sup>4</sup>. Once loaded, one of the two strands (having the same nucleotide sequence with that of mRNA) separates from the RISC complex and degrades. This strand, which degrades, is called a passenger strand, and the strand having the complementary sequence to that of target mRNA is known as guide RNA. The guide strand remains attached to the RISC and guides the complex to the target mRNA. After proper recognition of the mRNA nucleotide sequence, complementary to that of guide RNA, the cleavage process starts<sup>4</sup>. The silencing of the target gene takes place by cleaving the mRNA around 10 to 11 nucleotides upstream of 5' monophosphate end of the guide RNA. This process is catalysed with the help of enzyme Ago2, which is one of the most important components of RISCs. RISCs once cleave the target mRNA, undergoes recyclicalisation to carry out a similar event (**Error! Reference source not found.**)<sup>4</sup>. This model of target mRNA cleavage is supported by the *in-vitro* studies carried out by the Nykanen et al.<sup>5</sup>. They confirmed the formation of siRNA from dsRNA is ATP-dependent, loading of siRNA to the RISC is ATP-independent, unwinding of the siRNA complex to generate reactant complex is ATP-dependent and identification and cleavage of the target site of the mRNA are ATP-independent process. The group also confirmed the cleavage of the target mRNA at a single site precisely in the region complementary to the nucleotide sequence of guide siRNA<sup>5</sup>. Further, the Hutvagner et al.<sup>6</sup> established that the RISC is recycled to be used multiple times, confirming its catalytic nature.

### 3. SiRNA for cancer treatment

Current research in oncology is focused on understanding and targeting the genetic changes in the cancer cells. Recent knowledge of the genetic mutations in the cancer cells has allowed us to use classical chemotherapeutic agents in a better way. This knowledge is also helping us to develop advanced non-classical gene-based therapeutic agents<sup>7</sup>. Among the non-classical, siRNA is a useful therapeutic tool to knock-down the genes which are directly or indirectly responsible for the abnormal proliferation of cancerous cells. This possibility has fueled optimism in gene-based cancer therapy. In the near future, personalised treatment based on the genetic mutations will be possible, and siRNA is the

front runner among the therapeutic interventions. The incredible gene silencing ability of siRNA has proven to be the crucial tool in understanding the genetic functions in plants and animals. Elbashir et al.<sup>8</sup> first demonstrated the gene silencing ability of 21- and 22-nucleotide siRNA produced by the enzymatic action of ribonuclease III on dsRNA. They confirmed the inhibition of genes in various mammalian cell lines, including HeLa and human HEK. Following this demonstration, it was realized that this function of siRNA could be developed into a non-conventional new drug class that could directly inhibit the disease-causing or promoting genes. siRNA-based gene silencing is crucial for the targets which are not druggable or accessible to the small molecules, antibodies, or proteins<sup>9</sup>. Several *in-vivo* and *in-vitro* studies have confirmed that the abnormal cancerous cell proliferation could be significantly inhibited by siRNA-mediated silencing<sup>10</sup>. Moreover, siRNA has shown great promise in potentiating chemotherapy by sensitizing the drug-resistant cancer cells<sup>11,12</sup>. Present comprehensive research is also focused on the identification of the genes that, when silenced, boost the sensitivity towards chemotherapy. Therapeutic agents developed to target these mutated genes not only have the potential to target the cancerous cells but, rescue the healthy cells from the collateral damage<sup>13</sup>. In the present scenario, RNA interference is a widely used tool to identify and target them. Numerous studies reporting the use of siRNA on increasing the sensitivity towards chemotherapy *via* silencing are available; the detail is summarized in **Error! Reference source not found.**<sup>14-42</sup>.

Several genetic mutations in tumor suppressor and oncogene lead to the transformation of a normal to the cancerous cells. Numerous classical drugs target the critical signaling molecules and inhibit the proteins and enzymes which directly or indirectly alter the gene functions. In-depth knowledge of the loss of functions and gain of functions may help to use conventional medicines or investigate the new ones for better therapeutic outcomes. Loss of functions and gain of functions of onco- or tumor-suppressor genes could affect tumor growth, apoptosis, sensitivity to the chemo and radiotherapy, and development of resistance towards chemotherapy. Identification of the gene which enhances or inhibits the sensitivity towards the radiation or chemotherapy could be the attractive target for cancer treatment. Drugs identified to selectively target such genes have the potential to enhance the cytotoxic effect of therapy.

Nowadays, gene silencing by siRNA is a crucial tool to pinpoint the gene responsible for the specific pathological condition. With extensive siRNA libraries available, it's easy to identify the targets for selective and specific drug development. Such target identification also helps in exploring the role of



the particular set of genes in tumorigenesis<sup>43</sup>. Presently, the RNA interference tools like siRNA are widely used in studying the mammalian cellular signalling pathways. An in-depth exploration of cellular cell signalling pathways, especially in cancer cells, could help in the identification of the responsible genes. One very crucial example is the identification of the AKTcooperating kinases to enhance the action of Akt inhibitor. Morgan-Lappe et al.<sup>44</sup> identified AKT cooperating kinases by screening a library of kinase-specific siRNA to enhance the cytotoxic effect of AKT inhibitor A-443654. There are a few other crucial signalling molecules responsible for cancer identified using RNAi, such as 1) Aza-Blanc et al.<sup>45</sup> identified modulators of TRAIL-induced apoptosis. 2) MacKeigan et al.<sup>46</sup> identified phosphatases and kinases enzymes responsible for apoptosis and chemoresistance. 3) Futami et al.<sup>47</sup> identified molecules involved in Thapsigargin-induced apoptosis. 4) Brummelkamp et al.<sup>48</sup> confirmed that the loss of cylindromatosis activates NF- $\kappa$ B and inhibits apoptosis. 5) Berns et al.<sup>49</sup> in a large scale screening study carried out on human cells, identified several new components of the P53 cell signalling pathways. 6) Kittler et al.<sup>50</sup> identified several genes in HeLa cells, which are essential for cell division.

Several *in-vitro*, animal, preclinical, and some clinical trials have confirmed the sequence-specific binding of siRNA to the mRNA, and its site-specific cleavage results in the downregulation or inhibition of the genes responsible for cancer or other pathological conditions<sup>51</sup>. Irrespective of site-specificity, recent clinical trials have identified several hurdles in its clinical translation, which include degradation by the ribonucleases enzymes, stability of siRNA molecules in physiological conditions, inflammation reactions, site-specific and controlled release of siRNA, and efficient delivery vehicle. All these barriers must be overcome for the success of the siRNA in cancer treatment. Chemical modification may be required to improve the stability and reduce the immune activation of siRNA molecules<sup>52</sup>. The carrier system, which could not only deliver the siRNA molecules to the site of action but also protect it from the ribonucleases, is needed. PEGylated or tumour-targeting ligand conjugated nanoparticles composed of the lipids and other stimuli-sensitive polymers might improve the specificity and effectiveness of siRNA<sup>53</sup>. Although the siRNA has open new doors for the cancer treatment, it required fine-tuning to impart stability and delivery vehicle to carry it safely at the site of action. In the following section of the review, we have discussed the significant hurdles in siRNA delivery and the approaches which are under investigation for its safe and efficient delivery.

#### 4. Recent advances in siRNA delivery to cancer cells

Highly charged molecules like RNA have several unfavorable characteristics, like rapid nucleases base destruction, enhanced clearance by the kidney, immune activation, and inefficient delivery to the cancer cells, which hindered its development. One major problem is its physiochemical characters; they are hydrophilic, negatively charged, and have a high molecular weight, which makes it impossible to cross the lipid membrane of the cell. Moreover, if siRNA enters *via* endocytosis, they could be subjected to a rapid degradation process during endosome lysosome trafficking and could not pass through the nuclear membrane<sup>54</sup>. The therapeutic success of siRNAs in cancer not only depends on its delivery to the tumor site, but for the highest clinical benefit, it must be administered systemically or orally. For systemic delivery of the siRNA, the foremost hurdle clinical scientists facing are: 1) getting siRNA delivered to the specific gene site without affecting the healthy cells, 2) maintaining the optimum level of siRNA at the site of action, 3) enhancing its efficiency by increasing cellular uptake, and 4) monitor efficiencies. One of the approaches to overcome these challenges is the development of novel delivery systems. The ideal delivery system for the siRNA to the cancer cells should: 1) prevent the nuclease-based degradation, 2) promote targeted site delivery, 3) facilitate cellular internalization, 4) avoid endosomal pathway, and 5) release siRNA at the site of action<sup>54</sup>.

Several siRNA delivery platforms are under clinical investigation. Non-viral systems include lipid-based vectors (*e.g.*, liposomes, PEGylated liposomes, lipidoids, etc.), organic and inorganic nano-vectors, nanogels, peptide carriers (*e.g.*, cell-penetrating peptides), etc. Non-viral delivery systems could deliver the siRNA with lesser safety concerns. They are easy to prepare, highly stable, non-mutagenic with excellent transfection efficiencies.

##### 4.1. Lipid-based vectors to transport siRNA

Since the 1960s, liposomes underwent several changes that range from unilamellar vesicles composed of amphiphilic molecules to targeted liposomes for site-specific drug delivery<sup>55</sup>. Liposomes can entrap hydrophilic molecules in their aqueous core, whereas the hydrophobic molecules get trapped inside the lipid layer. One essential advancement is its upgrade to the stealth liposomes. Stealth liposomes contain lipids complexed with polymers, mostly PEG, in such a way that polymers are directed outwards from the liposomes. Such modification prevents the identification of the liposomes by the immune system and reduces the hepatic clearance. In targeted liposomes, functional lipids groups like  $-\text{COOH}$  or  $-\text{NH}_2$  are

present at the distal terminal of polymers, which help them to link with the targeting ligands (proteins, like peptides or antibodies). Functionalization at the distal terminal end could also help to introduce pH-sensitive or hydrolysable groups to develop the pH- or chemical-sensitive liposomes. Cationic liposomes are one of the promising variations of the liposomes composed/of the cationic lipids and zwitterionic lipids, also called as the helper lipids. When such positively charged liposomes encounter the DNA molecule, they form the complex called lipoplex due to the electrostatic attraction between positively charged liposomes and negatively charged DNA molecules. Such complex on binding with the cell surface undergoes fusion and introduces DNA molecules inside the cells<sup>56</sup>.

Felgner et al.<sup>57</sup> were the first who used the cationic lipids to transfect the cells with DNA. They used synthetic cationic lipid DOTMA for the preparation of liposomes. DOTMA facilitated the fusion of the liposomes with the lipid membrane of the cells. Fusion with the cell membrane has helped to achieve a high rate of DNA transfection<sup>57</sup>. During the last 30 years, different cationic lipids were developed to deliver the DNA and its products to the cells. Liposomes were the first delivery system developed from the cationic lipids. Most of the lipoplexes are not solely made up of the cationic lipids but are composed of the combination of lipids, such as DOPC or DOPE, CHOL, and some other natural lipids<sup>58-60</sup>.

Liposomes composed of the combination of helper lipids like DOPC, DOPE, and DSPC, are found to have a better fusion character than the liposomes made up of only the cationic lipids<sup>61</sup>. Overall, the loading of siRNA into the liposomes occurs because of the electrostatic charges; and sometimes, chances of nonspecific interactions with the serum or plasma proteins increased. Such non-specific interactions could lead to the activation of the immunogenic response and rapid clearance from the circulation system<sup>62</sup>.

#### **4.1. 1. Advanced cationic lipid-based siRNA delivery system**

Cholesterol or DOPE is added to the cationic formulation not only to enhance the stability of the liposomes but also to enhance its cellular uptake<sup>63</sup>. Helper cationic polymers were introduced in the formulation to increase the siRNA entrapment inside the liposome core. For example, protamine was added in the formulation (DOTAP/Chol) to increased siRNA entrapment<sup>64</sup>. To improve the siRNA loading capacity, cationic liposomes were formulated using AtuFECT01, neutral/helper lipid phospholipidDPhyPE, and DSPE-PEG<sup>65</sup>. The loading capacity of siRNA is also found to increase when it is modified chemically to conjugated to 2'-O-methyl, and 2'-fluoro and CHOL<sup>9</sup>. SiRNA modified with 4'-C-guanidinocarbohydrazidomethyl-5-methyl uridine was found to have better silencing efficiency.

Other notable modified siRNAs are GalNAc-conjugated siRNA, 2-OMe-phosphorodithioate-modified siRNA (higher loading capacity in RISC), CHOL-conjugated siRNAs (having better pharmacokinetic characters), hydroxyethylglycine PNA (*hegPNA*)-capped 3' and 5' siRNAs (protection against serum nucleases) and hydrophobically-modified siRNAs (improved stability and higher internalisation)<sup>66,67</sup>.

To improve the blood stability and pharmacokinetic characters, PEG was added to the cationic liposome formulation, which enhanced the blood circulation time<sup>68</sup>. A higher ratio of PEG enhances the circulation times but, at the same time, hampers the cellular uptake and endosomal escape, which means that the optimum ratio of the PEGylated lipids is essential<sup>69</sup>. Wrapsomes were proposed by Yagi et al.<sup>70</sup> where siRNA/DOTAP forms the core, and neutral lipid bilayer composed of egg phosphatidylcholine and PEG lipid forms the wrap. Wrapsomes were found to have improved circulation time along with higher stability<sup>70</sup>.

The drawback of PEGylation, *i.e.*, decreasing cellular uptake and endosomal escape, could be overcome by the approach of Carmona et al.<sup>71</sup> The group coupled PEG-2000 dialdehyde to the cationic liposome composed of cholesteryl polyamine-*N*<sup>1</sup>-cholesteryloxycarbonyl-3,7-diazanonane-1,9-diamine, neutral lipids (DOPE) and CHOL-PEG350 aminoxy lipid *via* oxime linkage. This linkage is stable at pH 7 but decomposes at pH 5, releasing the PEG but, at the same time, offers the advantage of PEGylation<sup>71</sup>. Such cationic liposomes linked with PEG *via* an oxime bridge could become an important delivery system for siRNA delivery in the acidic microenvironment of a tumor. Nanoparticles having PEG linked with lipids susceptible to the proteins like matrix metalloproteinase were also developed<sup>72</sup>.

Some biogenic materials like hyaluronic acid were also added in the cationic liposome formulation to reduce immune identification. Such nanoparticles were found to enhance the siRNA delivery-mediated silencing of luciferase in B16F10 tumor cells<sup>73</sup>. To take advantage of lipid-polymer-based nanoparticles, cationic lipid-polymer hybrid nanoparticles were prepared by a single-step nanoprecipitation of a cationic lipid (*N,N*-bis(2-hydroxyethyl)-*N*-methyl-*N*-(2-cholesteryloxycarbonyl aminoethyl) ammonium bromide, BHEM-Chol) and amphiphilic polymers for systemic delivery of siRNA. The lipid polymeric nanoparticles were found to efficiently deliver the siRNA to BT474 cells and, at the same time, escape the loaded siRNA from the endosome into the cytoplasm<sup>74</sup>.

To induce and enhance the cellular uptake and release of siRNA (endosomal escape), helper lipids like DOPE and 1,2-distearoyl-*sn*-glycero-3-phosphocholine were added to the formulation of the cationic liposome. Similarly, 3- $\beta$ -(*N*-[*N''*,*N''*-dimethylaminoethane] carbamoyl) cholesterol (DC-Chol)

and dioleoylphosphatidylethanolamine (DOPE)-based lipoplexes were found to enhance the transfection efficiency of the siRNA<sup>75</sup>.

#### 4.1.1.1. SNALP®

One of the critical developments in the cationic siRNA delivery system is the introduction of SNALP<sup>76</sup>. In general, SNALPs consist of modified siRNA, which is enclosed inside the bilayer membrane made up of cationic–zwitterionic lipids with an outermost shield of PEG. It is primarily made up of three distinct lipids: a cationic ionisable lipid (1,2-dilinoleyloxy-3-dimethylaminopropane), a helper lipid (Chol or fusogenic lipids), and a PEG lipid. The electrostatic force of attraction between the positive charge of the SNALP membrane and the negative charge of the cell membrane assists the process of cellular uptake<sup>76</sup>.

In a study reported by Morrissey et al.<sup>76</sup>, two siRNA, namely HBV263 and HBV1583, targeted to the hepatitis B virus were chemically modified to protect it from nucleases. The efficiency of these modified siRNAs was studied in the mouse model of hepatitis B virus by delivering it using SNALP system. Better efficacy of modified siRNA delivery *via* SNALP was observed when compared to the same but unmodified siRNA. At the same time, improved half-life in plasma was also noted. In 2006, Zimmermann et al.<sup>77</sup> have reported the first study of gene silencing in non-human primates. They described the silencing of the *APOB* gene, which is a target for heart disorders. *APOB*-specific siRNA entrapped inside the SNALP was administered *via* IV injection to the cynomolgus monkeys. SiRNA was found to cleave the mRNA at the site reported in the RNAi mechanism. Within the first 24 h, a reduction in the APOB protein and serum cholesterol was observed, and the effect persists for 11 days, indicating the importance of the SNALP system<sup>77</sup>. In a preclinical study, Judge et al.<sup>78</sup> delivered the siRNA targeting the *PLK1* and *KSP* in mice using SNALP. This report suggests the usefulness of the SNALP in delivering the siRNA load to the cancerous cells. Similarly, SNALP was used to deliver the microRNA (miR)-199b-5p. Delivery of miR-199b-5p was found to downregulate the HES1, and CSC levels in the colon ( HT-29, CaCo-2, and SW480), breast (MDA-MB231T, and MCF-7), prostate (PC-3), glioblastoma (U-87), and MB (Daoy, ONS-76, and UW-228) cells<sup>79</sup>. In another antiviral study, Geisbert et al.<sup>80</sup> silence the *Zaire Ebola* virus (ZEBOV) RNA polymerase by delivering siRNA using SNALP in guinea pigs model. miR-199b-5p administered using SNALP was found to hamper the proliferation with no sign of apoptosis. The effect of SNALP delivery system in the leukemia cell suspension was first reported by He et al<sup>81</sup>. In an attempt to improve the liver fibrosis treatment SNALP surface modified

with polypeptide, PPB was successfully used to deliver siRNAs against heat shock protein<sup>82</sup>. This data indicates that a system like SNALP is very critical in delivering the siRNA to the cancer cells without side effects<sup>79</sup>.

Recently, protein AXL which is involved in metastasis in both ovarian and uterine cancer was silenced by anti-AXL-siRNA using the novel delivery platform called p5RHH. P5RHH is composed of the cationic peptide (Melittin). When p5RHH enters the cell, it releases the siRNA upon protonation of histidine residue inside the acidic environment of endosomes<sup>83</sup>.

#### 4.1.1.2. Atuplex®

In 2011 a German-based biotech company developed a chemically modified siRNA, called AtuRNAi, and a delivery system (Atuple) for *in-vivo* application. The modified siRNA has the added advantage of better resistance towards the nucleases enzymes and higher stability in blood. As it has better stability, it is required in less quantity for the same therapeutic effects with a better half-life. SiRNA in this modified approach was kept as much natural/non-synthetic as possible by modifying the natural building blocks at only 2' sugar backbone position. No *in-vitro* and *in-vivo* induction in the genes associated with the inflammatory cytokines, including interferon, was observed. AtuRNAi products are available at a lower cost as compared with classical siRNA molecules. In addition, “silence therapeutics” has also developed a novel lipid-based delivery platform for AtuRNAi known as AtuPLEX. This proprietary owned complex is made to deliver AtuRNAi to the target cells *in vivo*. Atuplex composition involves the use of fusogenic lipids, which enhance the cellular uptake and assist the endosomal escape. This formulation was found very suitable for the delivery of therapeutic siRNA to inhibit the genes involved in the angiogenesis process. For specific requirements, “silence therapeutic” also included a PEG coating to prevent the interaction with blood protein and hide it from the macrophages. The company has around 50 patent applications covering different Atuplex compositions and uses. In one of the studies, “silence therapeutics” has reported the preclinical data of their AtuRNAi product called Atu027 for the treatment of solid tumors<sup>84,85</sup>.

#### 4.1.1.3. Rondel®

Rondel is another important nanotechnology-based delivery system for the siRNA. This system uses the electrostatic force of attraction between the negatively charges DNA or RNA molecules and the positively charged linear polymer with alternate cyclodextrin molecules<sup>85</sup>. Adamantane, which is highly water-soluble, is another essential component of the Rondel system present in the cyclodextrin cavity to

form the inclusion complex. PEG chains, linked to the inclusion complex on the outside of the nanoparticles, acts as a stabilizing agent and prevent its aggregation. A variety of the targeting ligands could be conjugated to the distal end of the PEG–adamantane–cyclodextrin inclusion complex to enable them to selectively link with the cells expressing the protein identified by the ligand. Chitosan is another low molecular weight carbohydrate used for the formation of nanoparticles to deliver siRNA. The rationale behind the use of such sugar type molecules was to impart the biocompatible character to the delivery system, to make them more stable in the biological fluids, and to enhance their transfection capabilities<sup>85</sup>.

As the name suggests, cyclodextrins are the linked glucose- $\alpha$  (1 $\rightarrow$ 4) molecules to form the circular basket shape. Hydroxy group of the sugar molecules in this basket topology are directed outwards, engulfing the upper and lower rim of the basket. In this configuration, the methinic protons (H-5 and H-3) are directed towards the inner cavity of the basket. These structural features impart the amphiphilic characters, enabling them to charge with the drugs of different physiochemical characters. This characteristic is utilized by pharmaceutical companies to develop an efficient drug delivery system for the poorly water-soluble, pH liable, or biodegradable drugs<sup>86–88</sup>.

Cyclodextrin molecule was selected for the RONDEL complex because of its low immunogenic character and toxicity, and its ability to acts as a basket and to form the non-covalent interactions with the hydrophobic molecules. In 1999, the first case of the cationic polymer cyclodextrin complex formation, characterisation, transfection efficiency, and successful delivery of plasmid DNA was reported<sup>89</sup>. To overcome the aggregation of cyclodextrin polymer and pDNA nanoparticles, neutral stabilising polymer, PEG was linked with the hydrophobic adamantane to form the stable complex<sup>85</sup>. Suzie Pun et al.<sup>90</sup> proposed the new method for polyplex modification, which utilized the ability of cyclodextrin polymer and adamantane to form the inclusion complexes. Non-PEGylated polyplexes were found to aggregate in the salt solution, whereas PEGylated polyplexes remained stable at the physiological salt solution. Linking of the targeting ligand to the PEG–adamantane conjugate further facilitated the site-specific receptor-mediated delivery of the complex. Galactosylated PEG adamantane inclusion complex was found to have a 10-fold higher efficiency than the un-galactosylated complex<sup>90</sup>. The first *in-vivo* proof of concept was proposed soon after the introduction of the murine model of Ewing's sarcoma<sup>91</sup>. The delivery system was composed of the cyclodextrin-containing polycation specifically used to bind and simultaneously protect the siRNA (siRNA for EWS/Fli1 fusion oncogene).

The transferrin protein was used as the targeting ligand to target the transferrin (Tf) receptor. The control, *i.e.*, without the transferrin conjugated to the polyplexes, has no antitumor effect<sup>91</sup>. PEGylated inclusion complex linked with transferrin complexed with the luciferase encoding gene when transfected to K562 leukaemia cells, resulting in better anti-cancer activity as compared to the inclusion complex with the linked transferrin protein (**Error! Reference source not found.**)<sup>92,93</sup>. Soon after the *in-vivo* success of the siRNA delivery, this concept was first commercialised by the pharmaceutical company (Calandi Pharmaceuticals) in 2008. Human Tf was used as the targeting agent to deliver the siRNA (siRNA targeting the M2 subunit of ribonucleotide reductase) using the cyclodextrin polycation delivery system (RONDEL) in the non-human primates<sup>93</sup>. The trade name of the product was CALAA-01. This siRNA delivery *via* transferrin-linked RONDEL inhibits tumor growth *via* RNA interference to reduce expression of the M2 subunit of ribonucleotide reductase (R2). Dose-dependent study of siRNA revealed the safety profile of the delivery system after the multiple systemic injections<sup>94</sup>.

#### 4.1.2. DC-Chol/DOPE cationic liposomes

Cationic liposomes, composed of DC-Chol and DOPE (DC-Chol/DOPE liposome), were used to deliver recombinant genes into established tumors. They are considered as the most efficient vector for the transfection of DNA into cells. Nabel et al.<sup>95</sup> had effectively delivered the human HLA-B7 gene into subcutaneous melanoma in clinical trials using DC-Chol/DOPE liposomes. The findings suggested that the transferred *HLA-B7* gene was expressed and localized to the site of injection, and no apparent toxicity or anti-DNA antibodies was formed, which indicated the successful delivery of these cationic liposomes DC-Chol/DOPE<sup>95</sup>. In another study, a double-blinded, placebo-controlled trial assessing the safety and efficacy of liposome-mediated DNA transfer to the nasal epithelia of cystic fibrosis patients using cationic liposomes DC-Chol/DOPE and an expression plasmid containing a human *CFTR* cDNA was conducted<sup>96</sup>.

DC-Chol/DOPE transfection system works well only when the lipids are present in the right proportion. A ratio of 3:2 or 1:1 of DC-Chol/DOPE in liposomes was found to have maximum transfection efficiency<sup>97</sup>. It was observed that DOPE is a crucial component of the transport system for the optimum function<sup>98</sup>. This system also has a similar issue of stability due to aggregation and immune identification, which could be overcome by PEGylation<sup>99</sup>. Although PEGylation enhances the transfection efficiency of the cationic liposomes, a very long chain and high density could affect the



transfection efficiency of the liposomes<sup>100</sup>. Various other factors could influence transfection efficiency<sup>75</sup>.

Maitani et al.<sup>98</sup> have prepared three formulations of liposomes in the ratio of 1:0, 3:2, and 1:2 (DC-Chol: DOPE) to evaluate the effect of chloroquine on endosomal escape. Chloroquine is known to increase the endosomal pH, and hence its impact on the formulation was studied. Pretreatment with the pH raising agent has shown no effect on formulation having the composition of 1:0 and 3:2, but has a profound effect on the formulation with 1:2 ratios in terms of reduced transfection efficiency<sup>98</sup>. As of today, DC-Chol/DOPE cationic liposomes are one of the best carrier systems available for the siRNA delivery to the cancer cells. But this has its own drawbacks, like not suitable for systematic delivery because of the aggregate's formation with blood protein. To overcome this issue, Lee et al.<sup>101</sup> have PEGylated the DC-Chol/DOPE cationic liposomes for kinesin spindle protein siRNA delivery to the cancer cells and to check its fate on systemic delivery. PEGylated composition was found to have a longer half-life in blood and enhance tumor accumulation as compared to non-PEGylated lipoplexes. PEGylated siRNA delivery has better silencing effects than the non-PEGylated siRNA and at the same time they remained hidden from the immune system of mice. These results indicated that in the coming days, DC-Chol/DOPE is better placed to deliver the siRNA *via* systemic delivery<sup>101</sup>. Liu et al.<sup>102</sup> have used DC-Chol/DOPE cationic liposomes system to deliver the siRNA against the ferritin to check its effects on iron homeostasis in glioma cells and chemosensitivity. On intratumoral injections of liposomes-containing ferritin siRNA, around 80% of ferritin protein inhibition was observed in two days. This decrease in the ferritin level was positively correlated with the enhanced chemosensitivity towards the carmustine<sup>102</sup>. To overcome the short-term gene silencing effects of siRNA, Seraj et al.<sup>103</sup> have designed Eg5shRNA-expressing plasmids to produce Eg5 hairpin RNA. To deliver this RNA, they used PEGylated DC-Chol/DOPE cationic liposomes and observed that the single systemic dose of Eg5 hairpin RNA expressing plasmid had long term Eg5 gene silencing effect in tumor-bearing mice. This system was also found to have no immunogenicity<sup>103</sup>. A study was reported by Tseng et al.<sup>104</sup> and found out the impact of disaccharides on the internalisation of plasmid on different vectors. Increased cellular delivery was observed when co-formulated with disaccharides<sup>104</sup>. The ability of DC-Chol/cholesterol liposomes to carry pDNA into 293T cells was investigated. A formulation containing cholesterol was found to have not only uniform particle size and lower turbidity, but also better transfection efficiency<sup>105,106</sup>. Among stimuli-sensitive cationic liposomes, pH-sensitive has very low transfection efficiency. To improve the transfection efficiency of pH-sensitive liposomes, Chen et al.<sup>107</sup> prepared

complexes containing DC-Chol and DOPE liposomes and pH-sensitive liposomes composed of CHEMS and DOPE, and evaluated the influence of various factors on pDNA transfection efficiency. All DC-Chol/DOPE liposome/pDNA and pH-sensitive liposome complexes showed similar pH sensitivity.<sup>107</sup> DC-Chol/DOPE cationic liposomes are optimised for transfection in the absence of serum. Further understanding of the difference between such compositions will lead to the better designing of the DC-Chol-DOPE liposomes. Transfection efficiency was further found to increase with the addition of protamine in the formulation<sup>108</sup>. Kisoan et al.<sup>109</sup> in one of their report, described the synthesis of the CHOL derivative  $3\beta$ [*N*-(*N*'*N*',*N*'-trimethylamino-propane)-carbomoyl] cholesterol, in which a propylamidooxy spacer separated the cationic trimethylamino head group from the hydrophobic and rigid cholesteryl ring system, and used them to make liposomes with an equimolar ratio of DOPE. The CHOL derivative, in combination with DOPE was found to provide better protection to the pDNA against the nuclease digestion and has better transfection efficiency<sup>109</sup>. To study the effect of PEGylation on gene silencing, Hattori et al.<sup>110</sup> used four types of cationic CHOL derivatives and three types of dialkyl or trialkyl cationic lipids and prepared seven types of PEGylated cationic lipoplexes that contained 1 % (mol/mol) PEG2000-DSPE. The PEGylation helped to reduce the aggregation with the blood components on intravenous injection. PEGylated cationic lipoplexes with *N,N*-dimethyl-*N*-octadecyloctadecan-1-aminium bromide has shown significant gene silencing effects in the lungs<sup>110</sup>. Overall, this study also revealed that 1 % (mol/mol) of PEG and variation in cationic lipids severely affected the gene silencing effects of siRNA. The selection of cationic lipids is critical for the success of the PEGylated cationic liposomes<sup>110</sup>.

Despite the success of cationic lipids, hurdles like endosomal escape, cytosolic delivery, and lipid toxicity are still restricting the exploration of its full potential. To address this critical challenge, Lechanteur et al.<sup>111,112</sup> prepared four different cationic liposomal formulations using DOTAP and DC-CHOL, and a different ratio of CHOL and DOPE. SiRNA was complexed with liposomes at six different siRNA/lipid molar ratios. The group confirmed that the nature of the lipid and lipid/siRNA ratio severely affected the cytotoxicity. It was observed that the cell-cell viability was reduced by 70% with liposomes composed of DOTAP/CHOL/DOPE (1/0.75/0.5) at a lipid/siRNA ratio of ten, whereas, at the molar ratio (Lipid/siRNA) of 2.5, the same formulation was found to be safe. For all the formulation, the transfection efficiency was found to be almost the same<sup>111,112</sup>.

Overall, for the successful development of CHOL/DOPE lipoplexes, it is not only essential to select the proper cationic lipids, but the ratio of lipids to siRNA plays a crucial role. Another critical point to be noted is that the acidity of exosomes plays a vital role in the exosomal escape. Hence it is essential to stress the proper selection of pH-sensitive lipids.

## 5. Lipid-protamine–DNA/hyaluronic acid (LPD/LPH) nanoparticles

The effort to improve the transfection efficacy of the cationic liposomes is focused on the development of the new cationic lipids and polymers. Theoretically, cationic lipids or polymers having multiple positive charges shall have better transfection efficiency as compared to the monovalent cationic lipids. So the increase in the overall negative charges on the RNA or DNA molecules with the simultaneous increase in the positive charges on the cationic lipids could have better electrostatic charges and transfection efficiency<sup>113</sup>. Research in this area is mostly based on the trail, and hence enhancing the transfection efficiency of the existing cationic polymers is desirable.

One of the significant disadvantages of the DC-CHOL liposomes is its low transfection efficiency because of the larger nucleic acid/liposome complexes. The size of this complex at optimum nucleic acid to liposome ratio varies between 0.6–1  $\mu\text{m}$ <sup>95</sup>. Liposomal complex aggregates to form the larger particles. However, several measured are under consideration to prevent aggregation. For example, in a clinical trial for malignancy treatment, DMRIE/DOPE, a cationic liposome was prepared, which does not aggregate to form the larger particles<sup>114</sup>. DC-CHOL/DOP liposome was prepared to transfect the *CFTR* gene and restores its activity in cystic fibrosis patients. This liposome has shown no sign of aggregation and achieved maximum transfection with altered transfection protocol. DNA/Liposome complex was prepared at high pH 8 to prevent the aggregation<sup>96</sup>.

Wagner et al.<sup>115</sup> have shown that the shape of the DNA-Liposome complex plays a crucial role in the receptor-mediated endocytosis of the targeted ligand linked liposomes. In this transfection system, transferrin conjugated to the liposome acted as a targeting ligand, and polycation part acted as the counterpart for the electrostatic link with the negatively charged transferrin molecule. Polycation also squeezed the DNA molecules to form the doughnut-shaped delivery system. The degree of DNA condensation was found to be directly linked with the transfection efficiency. In this study, it was revealed that replacement of the large portion of the transferrin polylysine with free polylysine, improved the transfection efficacy of the delivery system. The addition of free polycation could further

enhance transfection efficiency. It was also observed that protamine and histone could also be replaced with the polycationic part to get condensation of the DNA<sup>115</sup>.

Gao et al.<sup>116</sup> tested some high molecular weight cationic polymers to check their effects on the transfection efficiency of the cationic liposomes. Poly(L-lysine), poly(L-ornithine), and poly(D-lysine) and polybrene were found to be equally effective in potentiating the transfection efficiency. However, the treatment of cationic liposomes with poly(D-lysine) or polybrene has led to deleterious effects on the cell, indicating that poly(L-lysine) or protamine are the safer alternatives to enhance the transfecting effect of the cationic liposomes. Gao et al.<sup>117</sup> again in 2013 developed liposome–polycation–DNA complex functionalised with anti-epidermal growth factor receptor Fab' antibody to target the epidermal growth factor receptor of the hepatocyte.

Clinical application of LPD to deliver siRNA to target *C-MYC*, *MDM2*, and *VEGF* by LPD was investigated. Silencing of these genes using LPD delivered siRNA lead to the reduction in the metastasis events of B16F10 melanoma cells *in vivo*. This study indicates that the LDH could be the most desirable tool to deliver the siRNAs to the cancer cells and could be the base for the future drug delivery system<sup>118</sup>.

The concept was proved valid with the development of PEGylated LPD (LPD–PEG–anisamide) nanoparticles, which boosted the siRNA delivery to cancer cells and simultaneous silencing of the associated gene, leading to the cancer cell growth inhibition<sup>119</sup>. SiRNA against the survivin, delivered by LPD–PEG–AA was not only found to induce the apoptosis process but also sensitize the cancer cells towards the cisplatin<sup>64</sup>.

Similarly, siRNA against *EGFR* delivered by LPD–PEG–AA was found to inhibit the EGFR expression in the cancer cells along with enhancing apoptosis<sup>120</sup>. These studies indicate that the targeted liposomes could be a powerful tool to deliver siRNA to the cancer cells. One of the most critical characters of the efficient delivery system is its inertness towards the immune system. On this front LPD system has little toxicity and inertness as confirmed by Chono et al<sup>73</sup>. The group has developed an LPD nanosystem to deliver siRNA systematically to the cancer cells. Cationic liposomes formed by mixing protamine, hyaluronic acid, and siRNA were coated with the cationic polymers. The complex thus formed again modified by adding lipids DSPE–PEG or by adding targeted PEGylated lipids like DSPE–PEG–anisamide. Anisamide is the ligand for the receptor expressed on the B16F10 melanoma cells. The

liposome system developed had higher loading and transfection efficacy along with the low immunotoxicity in the dose range of 0.15–1.2 mg siRNA/kg<sup>73</sup>.

Two important issues of the siRNA therapy and delivery system are the 1) non-specific delivery, including poor uptake by the cancer cells, and 2) unfavorable pharmacokinetics, including nucleases degradation and rapid clearance from the systematic circulation. Both issues were tried to be resolved by Chen et al.<sup>121</sup> by delivering siRNA and DOX together. The group developed LPD nanoparticles for the site-specific delivery of the siRNA to the cancer cell of the mice by modifying LPD system with the NGR (asparagine–glycine–arginine) peptide. NGR is a ligand for the aminopeptidase N (CD13), mostly overexpressed in the tumor cells. The system was found to be efficient in delivering the siRNA to the cells and successfully down-regulate the target gene in HT-1080 cells<sup>121</sup>.

Chen et al.<sup>122</sup> confirmed that the c-MYC siRNA could sensitize the cancer cells towards the paclitaxel. PEGylation plays a vital role in the stability of the nanoparticles; hence, to determine the efficiency of the PEG linker, Deng et al.<sup>123</sup> compared the siRNA delivery efficiency of DSPE-PEG-COOH or DSPE-PEG-MAL derivatives linked with the anti-EGFR Fab' *via* a post-insertion approach. Immuno LPD, where anti-EGFR Fab' linked through the DSPE-PEG-MAL conjugation, was found to be more efficient in delivering the siRNA to the target cell than the nanoparticles where anti-EGFR Fab' was linked *via* DSPE-PEG-COOH linkage<sup>123</sup>.

Overall, siRNA is the crucial tool in gene therapy, and its delivery to the target cell is a critical barrier to overcome. A combination of siRNA and chemotherapeutic agents has recently achieved tremendous attention because of their synergistic action, better anti-cancer activity, low side effects, and fewer incidence of the drug resistance emergence. In combination therapy, siRNA and chemotherapeutic agents must have the synergistic action and should not have the antagonistic impact. To make cancer therapy more specific and safer, liposomal delivery using the targeting ligand significantly improves the efficiency of chemo and gene therapy. LPD not only offers the opportunity of delivering the siRNA/chemotherapeutic agents, but can also deliver the siRNA/therapeutic agent specifically to cancer cells if modified to link them with the targeting ligand, thereby avoiding the side effects. The following **Error! Reference source not found.**<sup>124–129</sup> represents the various valuable work carried out in the chemotherapeutic delivery to the cancer cells using LPDs.

### 5.1. Lipid/phosphate/calcium nanoparticles (LCP)

Despite the LPD success in delivering therapeutic siRNA to the cancer cells, improvement in terms of cellular uptake and bioavailability is required. LPC in terms of assembly is similar to the LPD except that the core of LPD is substituted with siRNA trapped nano-size calcium phosphate precipitate prepared by water-in-oil micro-emulsions<sup>130</sup>. This particular system was first reported by Li et al.<sup>130</sup> in 2010, describing its utility in siRNA delivery. It was hypothesised that the inorganic ion would degrade inside the acidic pH of the exosome, leading to swelling and bursting, and ultimately release siRNA trapped inside it. PEGylation was further carried out, and anisamide, which is a ligand for the sigma-1 receptor, was conjugated. In their study, siRNA against luciferase was used as a model to predict the gene silencing effect of this new carrier in H-460 cells. Nanoparticles conjugated with the targeting agent, anisamide, have shown better gene silencing effects than the unconjugated. This formulation was also found better when compared with LPD.

In LPD, which was reported by the same group, the DNA protamine complex was wrapped by the cationic liposome to form the positively charged particles. The positively charged particle then was further modified to include PEG and target ligands to impart site-specific delivery and better circulation time. This system, though successful, needed improvement in terms of endosomal escape. To overcome this issue, LCP nanoparticles were proposed. The 1st generation LCP (LCP-I) was made up of citrate-stabilized calcium phosphate core wrapped by cationic liposomes. The particle thus formed are suitable for the post-insertion of PEG and ligand conjugation<sup>131</sup>. The process of purification of LCP-I was tedious; hence, second generation LCP-II was proposed by Huang et al.<sup>131</sup> (**Error! Reference source not found.**). In LCP-II, a lipid called DOPA was introduced inside the core to stabilize the nanocarriers. A similar reverse microemulsion method was used for their preparation. However, the sodium citrate was replaced with DOPA. In both LCP-I and LCP-II, the entrapment of siRNA or DNA occurred at the precipitation step. Other than siRNA, DNA chemotherapeutic agents having phosphate groups are the good candidates for LCP encapsulation<sup>131</sup>.

LCP is now the best-known nanocarriers for its efficiency in delivering the siRNA to the cancer cells. This efficiency is related to the fact that calcium and phosphate rapidly dissolve at the acidic pH of endosomes. This causes endosomal degradation, releasing the siRNA into the cytoplasm. Several modifications are still underway to modify this system for better delivery property. Maitra et al.<sup>132</sup> have reported the preparation of calcium phosphate nanoparticles using a reverse microemulsion environment. The calcium phosphate colloidal system undergoes aggregation over the period of time,

creating a severe stability issue. To overcome this issue, Sokolova et al.<sup>133</sup> have developed a rapid precipitation method of calcium phosphate nanocarrier formation. This colloidal system has shown better stability over a period of time. To further explore the efficacy of the calcium phosphate nanoparticle, Liu et al.<sup>134</sup> have developed the nanocarriers of 23.5–34.5 nm in diameters. This calcium phosphate system was found to be very efficient in delivering the DNA molecules with a very high transfection rate at the same time protecting DNA from degradation<sup>134</sup>. This system was also used to deliver DNA molecules by transfecting plasmid DNA<sup>135</sup>. Polyacrylic acid/calcium phosphate nanoparticles were reported by Wang et al.<sup>136</sup> for delivering drug to the cancer cells. Radionuclide-like <sup>177</sup>Lu and <sup>111</sup>In were also successfully encapsulated inside the LCP along with the chemotherapeutic agents<sup>137</sup>.

Over the years, the LCP has shown success not only in delivering the siRNA molecules but also other treatment and imaging agents. In the future, there are many opportunities to combine the efficiency of LCP with other carriers for the simultaneous delivery of therapeutic and imaging agents.

## 5.2. *Inorganic nanoparticles*

Inorganic nanoparticles are most extensively used as an imaging probe because of their unique chemical and physical features that arise from their nanoscale size<sup>138</sup>. Several nanoparticle probes for imaging were developed using their magnetic, optical, and X-ray attenuation properties. Elements like gold, bismuth, and silver have been successfully used to contrast images of CT scans because of their high X-ray attenuation properties<sup>139–141</sup>. Similarly, inorganic elements and compounds like silver, gold, iron oxide, and silica were studied to analyze their utilization in drug delivery systems<sup>142,143</sup>. Only a few of these nanoparticle has reached to the advance stage, and most of them are in the initial phase of clinical development.

Moreover, silver and gold nanoparticles possess the peculiar optical property of surface plasmon resonance, which makes them different for the liposomes, micelles, and dendrimers<sup>144</sup>. Surface plasmon resonance is the basic principle behind several color-based biosensor techniques. It is an oscillation of conduction electrons at the interface between negative and positive permittivity material stimulated by incident light<sup>144</sup>. Surface plasmon resonance helps to measure the adsorption of materials on the planer surface of metal like gold and silver. Furthermore, because of their biocompatibility, they are now being explored to deliver DNA base product to the cytosol.

Drugs can be conjugated with the gold nanoparticles *via* covalent or electrostatic bonding and could be released inside the cells by external or biological stimuli<sup>145</sup>. Silver has reported antibacterial activity; however, few reports have been published confirming the use of silver nanoparticles for drug delivery. Prusty et al.<sup>146</sup> developed stimuli-responsive polyacrylamide/dextran nanohydrogels composites material by *in situ* polymerization technique with incorporated reduced nanosilver. Jain et al.<sup>147</sup> prepared iron oxide nanoparticles to target the anthracycline antibiotic violamycin B1 to breast cancer. Cytotoxicity and the anti-proliferation effects of nanoparticles were tested *in vitro* on the breast adenocarcinoma cell line (MCF-7)<sup>147</sup>. Ngamcherdtrakul et al.<sup>148</sup> developed the 47 nm mesoporous silica nanoparticle core coated with a crosslinked polyethyleneimine–polyethylene-glycol copolymer, conjugated with anti-human epidermal growth factor receptor type 2 siRNA and trastuzumab (a monoclonal antibody against human epidermal growth factor receptor). This nanoparticle was developed to enhance the half-life of siRNA in blood and DNA silencing effect of siRNA by explicitly targeting the cancer cells<sup>148</sup>.

Overall, the inorganic particles provide a useful medium for the development of the delivery vehicle for the siRNA<sup>149</sup>. They offer a high surface area to volume ratio, which ensures the high conjugation of siRNA and hence better loading. A crucial key to the success of the inorganic nanoparticle delivery system is the flexible surface chemistry, which provides the means to overcome the hurdles of safe siRNA delivery<sup>150</sup>. Additionally, it is easy to track the siRNA delivery to the cells because of their unique physical and chemical properties<sup>151</sup>.

Among the inorganic nanoparticles, because of their inertness, nontoxicity, and biocompatibility properties, gold nanoparticles are the most widely studied for siRNA delivery<sup>151</sup>. Strong interaction between sulfur and gold (S–Au bond) elements helps to conjugate the biological and synthetic compounds on to the surface of gold nanoparticles<sup>152</sup>. S–Au bond is composed of around 35% of partial covalent and 64% electrostatic characters<sup>153</sup>. An energy decomposition analysis indicated that gold had a greater covalent character with sulfur ligands relative to Cu and Ag<sup>154</sup>. Covalent linking to the gold nanoparticles did not affect and inhibit siRNA's biological activity<sup>155</sup>.

In recent times the research interest is grown significantly in polyvalent oligonucleotide nanoparticle conjugates, which consist of the core of the 2–250 nm, and several strands of oligonucleotide covalently conjugated to it<sup>156</sup>. The polyvalent oligonucleotide nanoparticle conjugates possess unique properties like cooperative binding, higher complementary strand binding, catalytic properties, easy intracellular entry without the use of additional transfection agents, and higher



intracellular stability and resistance toward the nuclease enzymes, which makes them the potential candidate for gene silencing<sup>157-161</sup>. Seferos et al.<sup>156</sup> examined the polyvalent oligonucleotide nanoparticle conjugates and explained the enzymatic resistance and intracellular stability. For stability study, they prepared 1 nm gold nanoparticles and functionalized them with the 20 base pair long oligonucleotides linked *via* 10 base pair linker DNA and propylthiol anchor<sup>156</sup>. The thick coat of oligonucleotides on the surface of nanoparticles was found to protect them against the enzymatic degradation of nucleases enzyme.

For conjugation, thiolate oligonucleotide reacted with the citrated-capped gold nanoparticles. During the reaction, oligonucleotide ligands displaced the citrate group of the gold nanoparticles and formed the gold thiol bond. Sodium chloride could be used to stabilize the charge repulsion, thereby allowing the more oligonucleotides to conjugate on the surface to create the dense monolayer coat. Around 250 nucleotides could be comfortably conjugate on the surface area of the gold nanoparticle of 15 nm size to give rise to polyvalent complex<sup>161</sup>. This conjugation method was successfully used to conjugate the oligonucleotide to the nanoparticles of the size between 2 to 250 nm<sup>162</sup>. Irrespective of the high negative charge, which could prevent the cellular uptake, polyvalent oligonucleotide gold nanoparticles have remarkable uptake, as seen in more than 50 different cell lines<sup>163,164</sup>. Cellular uptake was found to be the function of the oligonucleotide density on the nanoparticles; higher density was found to support the more efficient delivery<sup>157,160</sup>. The uptake of anionic nanoparticles (oligonucleotide conjugated) is attributed to the strong binding with the scavenger receptor, which is an essential protein involved in the receptor-mediated membrane transport system. The superfamily of the scavenger receptor proteins could bind different types of ligands, including polyanionic compounds like lipoproteins, apoptotic cells, cholesterol ester, phospholipids, proteoglycans, ferritin, and carbohydrates<sup>165</sup>. This recognition of the wide range of compounds allows the scavenger proteins to play a crucial role in pathology and homeostasis. Scavenger receptor protein undergoes endocytosis after binding to the ligands. This mechanism provides the universal mechanism of delivery to the healthy and disease cells. Targeted delivery to the cells over-expressing the surface proteins is also possible by conjugating the antibody against such protein to the polyvalent oligonucleotide gold nanoparticles<sup>166</sup>.

Hao et al.<sup>167</sup> used synthetic tumor suppressor microRNA (miR-205) to conjugate with the oligonucleotide gold nanoparticles. These miRNA-conjugated polyvalent oligonucleotide gold nanoparticles were found to successfully inhibited the expression of the target protein<sup>167</sup>. Oishi et al.<sup>168</sup>

developed the delivery system for siRNA by complexing the thiolated siRNA with the gold nanoparticle to which poly(ethylene glycol)-*b*poly(2-(*N,N*-dimethylamino)ethyl methacrylate) was conjugated. siRNA was found to significantly suppress the expression of luciferase expression in HuH cell line. Giljohann et al.<sup>169</sup> reported the RNase-free polyvalent siRNA gold nanoparticles to silence the gene in HeLa cells. This siRNA-conjugated gold nanoparticle was found to have the six-time longer shelf life in the serum than their RNA duplex counterparts. The functionalization with siRNA leads to the development of nanoparticle with better cellular uptake without the need for chemical modifications or the use of other transfection medium<sup>169</sup>.

Local suppression of the genes in the skin presents the unique challenge of negative charge of large molecules like siRNA delivery. Zheng et al.<sup>170</sup> reported the spherical nucleic acid nanoparticle conjugates, gold cores with conjugated siRNA. The siRNA conjugated nanoparticles were found to freely pass through 100% of skin cells *in vitro*, mouse and human epidermis within hours after application<sup>170</sup>. When siRNA against *EGFR* was delivered using this system locally to the skin of a hairless mouse, complete inhibition of EGFR expression and downstream ERK phosphorylation were observed<sup>170</sup>.

The success of siRNA delivery system depends on the endosomal escape, and this is also true in the case of the siRNA-conjugated inorganic nanoparticles. Massich et al.<sup>171</sup> successfully demonstrated the endosomal escape of the siRNA after 4 h from the polyvalent nucleotide gold nanoparticles by tagging them with cyanine 5.

As discussed earlier, various cationic materials like lipids and polymers were used to condense the siRNA to form the nanoparticles. Additionally, various functionalized nanomaterials, like carbon nanotubes, iron oxide nanoparticles and gold nanoparticles, were also used to condense the siRNA for delivery<sup>172-174</sup>. These materials were also found to reduce toxicity as compared to the polymers<sup>175</sup>.

Compared to the plasmid size DNA, siRNA usually has less efficient interactions with the cationic materials because of the small size. Hence, siRNA required a high concentration of such materials for efficient compression or a material with high cationic characters. To overcome this issue, gold nanoparticles with conjugated cationic ligands were used for better interactions. Kim et al.<sup>175</sup> reported the gold nanoparticles conjugated with dendritic PEI-like ligands to enhance the cationic characters. The siRNA-conjugated supermolecule developed using this protocol was found to have good gene inhibition activity with low toxicity<sup>175</sup>. Similarly, for the treatment of breast cancer, Fitzgerald et al.<sup>176</sup>

developed coated gold nanoparticles with poly(ethylenimine) to produce the poly(ethylenimine)–gold nanoparticles complex. The complex was further conjugated with the targeting ligand anisamide to produce a cancer cell-targeted siRNA delivery system. Anisamids is the ligand for the sigma receptor, which is overexpressed on prostate cancer cells<sup>176</sup>. To silence the ROR1 oncogene, which is overexpressed in different cancers, Ahwazi et al.<sup>177</sup> immobilized HIV - 1 TAT peptide on gold nanoparticles and conjugated the particles with the ROR1–siRNA for the potential breast cancer treatment. In an alternative approach Shirazi et al.<sup>178</sup> synthesized and conjugated homochiral L-cyclic peptide to the gold nanoparticle to deliver the siRNA in HeLa cells. For the Dengue treatment, Paul et al.<sup>179</sup> conjugated anti-DENV siRNAs with gold nanoparticles (AuNPs) and tested them *in vitro*.

Overall, among inorganic materials, gold nanoparticles have shown the potential to be the preferential delivery agent for the siRNA. Reports of various ligands, like cell-penetrating peptides, protein, antibody covalently linked to the gold nanoparticles, are available. These ligands have shown promising results for siRNA delivery<sup>7,180</sup>. The siRNA conjugated to the gold nanoparticles has shown resistance towards the nuclease-based degradation and promoted the timely endosomal release. However, such ligand–gold nanoparticles lack serum stability and have a very short self-life, which prevents its long-lasting gene silencing effect. S–Au covalent chemistry is the most direct method to conjugate siRNA to gold nanoparticles. Oishi et al.<sup>168</sup>. used S–Au chemistry to conjugate the siRNA to gold nanoparticles. They prepared 15 nm gold nanoparticles and conjugated it with S–PEG<sub>5000</sub>–PAMA<sub>7500</sub> polymer followed by linking them with the thiolated siRNA. Jensen et al.<sup>181</sup> extended this concept to produce spherical nucleic acid-linked gold nanoparticles. They used this system to knockdown the *Bcl2L12* mRNA using the siRNA against it in glioma cells<sup>181</sup>. Gold nanoparticles covalently linked with the siRNA was further coated with streptavidin layer to attach cell-penetrating peptides through biotin-streptavidin ligation<sup>182</sup>. Gold nanoparticles are also developed into the advanced platform for targeted delivery. For example, thiol–siRNA and Arg–Gly–Asp were simultaneously conjugated to the gold nanoparticles to carry the siRNA to the lung tumor cells in the murine model.

The more convenient conjugation method to conjugate the siRNA is the non-covalent linking. Non-covalent linking is facilitated by the electrostatic attraction between the negatively charged siRNA and positively charged nanoparticles. For example, Kim et al.<sup>175</sup> reported the gold nanoparticles conjugated with dendritic PEI-like ligands to enhance the cationic characters, which were later conjugated with the negatively charged siRNA. For instance, cationic polymer like polylysine was also used to functionalize

the gold nanoparticles, which was later used to entrap the siRNA for delivery<sup>183</sup>. One advanced method of siRNA conjugations is layer by layer coating of gold nanoparticles with alternate layers of cationic polymer and siRNA to give rise to the coat of gold nanoparticle–cationic polymer–siRNA–cationic polymer. Elbakry et al.<sup>184</sup> developed the gold nanoparticle using layer by layer approach and further investigated its usefulness in siRNA delivery. Similarly, Lee et al.<sup>186</sup> for hyaluronic receptor-mediated siRNA delivery have developed the cysteamine-modified gold nanoparticles layered with siRNA–polyethyleneimine–hyaluronic acid. For extended gene silencing and lower toxicity, Lee et al.<sup>186</sup> have used protease degradable polylysine as a biodegradable biopolymer. They conjugated the gold nanoparticles with the siRNA, which were then coated with the polylysine. The layer of poly-lysine was then degraded by the lysosomal cathepsin B enzyme ensuring the extended-release of siRNA<sup>185,186</sup>.

Inorganic nanoparticles have provided the unique stage for the effective delivery of siRNA to the cancer cells. Delivery of siRNA using organic nanoparticles can be fine-tuned by modifying the nanoparticle surface. As discussed, inorganic nanoparticles possess the unique physical and optical properties which could be used to track the fate of such particles inside the body. The potential of organic potential is not only limited to the siRNA delivery but could be used for diagnostic purpose. Despite the several advantages, several hurdles needed to be overcome to translate the lab research to the patients on the bed. For clinical translation, precise information about the safest route of administration, toxicity, immune response, long and sustained release of the siRNA is required. Overcoming these hurdles will need a better understanding of the central aspects of inorganic nanoparticle relation with living systems. Research on such interaction will ensure the faster translation of lab research to the clinical trials.

### 5.3. *Micelles for siRNA delivery*

Polymeric micelles are another nanocarrier system which has attracted remarkable attention as a potential carrier to deliver siRNA to the cancer cells. Micelles are made up of the blocks of the two or more polymers having an opposite affinity towards the same solvent. Thus, polymers of the micelles have amphiphilic characters. These amphiphilic block polymers, when suspended in a solvent, organized themselves to form the micelles depending upon the block affinity towards the solvent. If the diblock polymer suspends in the aqueous phase, the hydrophobic end of the polymer attempts to stay away from the aqueous phase forming the core of the micelles. In contrast, the hydrophilic part will face the

aqueous phase forming the micelle shell. The formation of micelles only occurs at the concentration above the critical micelles concentration (CMC). Generally, micelles forming at the lower CMC are more stable and better to deliver the siRNA to the cancer cells. Polymers with high hydrophobicity characters exhibit better stability due to the lower CMC. In aqueous solution, less water-soluble compounds get trapped inside the hydrophobic core of the micelles, whereas the compounds with the higher hydrophilic characters remain in the intermediate layer<sup>187</sup>.

Micelles could be divided into two broad categories (**Error! Reference source not found.**): 1) formed from the direct linking of the PEG through non-degradable linkages to siRNA to form the PEG–siRNA complex; 2) formed from the direct condensation of the siRNA with the block amphiphilic polymers containing the polycations followed by micellization of block copolymer/siRNA complex<sup>188</sup>.

The advantage of the polymeric micelles is their ability to solubilize the water-insoluble compounds inside its core. This system helps to enhance the bioavailability of the drugs, the full potential of which is difficult to explore because of unfavorable pharmaceutical characters. Due to the low water solubility, it is sometimes challenging to achieve the complete therapeutic outcome of the compound. Most of the anticancer drugs are polycyclic compounds, hence has to face the same pharmaceutical challenges. If such drugs are administered *via* the parenteral route, the chances of building aggregates large enough to block small capillaries are very high<sup>189</sup>. Polymeric micelles could not only enhance bioavailability by inhibiting rapid extraction and solubilizing compounds at the core but also deliver them at the site of action if they are conjugated with the targeting ligands. Another distinct advantage of the micelles is its size (10–100 nm), which is small enough to remain in the circulatory system by avoiding the mononuclear phagocytic system and large enough to prevent fast renal clearance<sup>190</sup>. Further, leaky vasculature of the tumor helps the higher accumulation of the micelles *via* EPR effect<sup>191</sup>. Polymeric micelles formed at the lower CMC offer higher stability even if diluted in the higher volume of the body fluids, which allows the hydrophobic compounds to remain inside the core being protected for a longer time.

### 5.3.1 *Passive and active micelles targeting*

Polymeric micelles are 10 to 100 nm diameter nanocarriers. The hydrophobic core of the micelles carries the water-insoluble drugs, whereas the hydrophilic component helps to hide the assembly from RES and enhances its blood circulation time. This property allows micelles to accumulate passively (passive targeting) in the tumor having leaky vasculature (hypoxic tumors). Furthermore, the flexibility

of the block copolymer chemistry permits the easy alteration of micelles structure according to the physical and chemical properties of the drug, ligand conjugation, tumor environment, and sensitiveness to external and internal stimuli. The features and functions of active and passive micelles targeting are summarized in **Error! Reference source not found.**<sup>192–198</sup>.

### 5.3.2. Stimuli-responsive polymeric micelles

Distinct characters of the cancer cells or tumor microenvironment act as a stimulus of the drug release. In general, micelles made for such a stimulus carry the drug in one environment (extracellular or in normal tissue environment) and release it when such micelles enter in the distinct environment of the tumor and cancerous cells<sup>199</sup>. Polymeric diblocks could be used to prepare such micelles to respond to the intrinsic (redox potential, enzymes, cofactors, enzymatic products, and pH) or extrinsic stimuli (ultrasound, external magnetic field, temperature, and light). Stimulus-sensitive micelles release the drug load after the structural change/destruction in response to the external or internal stimuli. These stimuli generally lead to the destruction of the micelles *via* polymerization, aggregation, disintegration and isomerization, etc.<sup>199</sup>. The most common stimuli-responsive micelles are discussed in **Error! Reference source not found.**<sup>187,200–204</sup>.

### 5.3.3. Recent multifunctional micelles delivery of siRNA to cancer cells

Recent approaches allow the integration of the best of different physical and chemical characters into single multifunctional micelles. When different functionalities were combining in a new hybrid micelle where each component is working in complete harmony and coordination with the other to give the simultaneous or sequential drugs/siRNA/diagnostic agents, such hybrid micelles are termed as multifunctional micelles. Thus, the ideal multifunction micelles could not only deliver the therapeutic agents but, if required, should also be able to deliver the diagnostic agents. Cancer, which is a multifactorial disease, is not only difficult to treat, but the perfect diagnosis is challenging. Recent advances in molecular therapies have developed very selective treatments. However, some of the cancer cells remain undetected, develop resistance over the period of time, and lead to therapy failure. Cancer cells and tumor environment have several distinct characters which differentiate them from the normal cells and tissue microenvironment<sup>205</sup>, which includes several deregulated protein expression, pH, distinct vasculature development, etc. Hence cancer requires a multi-faceted therapeutic and diagnostic

approach. Considering all the distinct characters of the cancer cells and the versatility of the micelles to carry the different load, it becomes imperative to use multifunctional micelles for the treatment. Although incorporating all the ideal characters of drug delivery into one single vehicle is difficult, a blending of two or more characters is possible and is necessary for the cancer treatment. In recent times the research focused on the development of the multifunctional micelles to enhance the delivery efficiency, minimized the side effects, and simultaneous delivery of diagnostic agents. The recently reported multifunctional approaches are discussed in **Error! Reference source not found.**<sup>206–228</sup>.

Based on the literature review, the two common strategies employed to make the polymeric micelles involves: 1) direct conjugation of siRNA to hydrophilic (PEG) or hydrophobic (lipids) *via* non-degradable or degradable linkages. This is followed by their exposure to the polycations to form the micellar structures called polyion complex micelles (PIC). Poly(aspartic acid) or poly(L-lysine) or PEI is the most commonly used polyion segment<sup>229</sup>. 2) SiRNAs are complexed with an amphiphilic block copolymer having polycations segments followed by the micellization of the complex<sup>230</sup>. Nanocarriers, including micelles, cross the cell membrane by the endocytosis process. One of the significant causes of concern is the endosomal escape after endocytosis. SiRNA inside the endosomes are nothing better than outside the cells. They need to escape out of the endosomes to avoid the lysosome's lower pH (pH ~4.5) and potential degradation. Endosomal escape makes the siRNA available in the cytosol to form the silencing complex. Cationic polymers are hence incorporated in the polymeric micelles, which release siRNA by disturbing the endosomes. Some polymeric micelles also included pH-sensitive polymers, which, when exposed to the endosomal pH, disrupt the endosomes and release siRNAs in the cytosol. Some micelles formulations utilized polymers, which, when exposed to the external stimuli like light or magnetic fields, destabilized the endosomes to release the siRNAs. Considering the current literature discussed in this section, we can assume that the multifunctional polymeric micelles are one of the front runners to establish itself as the best delivery option to carry siRNA inside the cancer cells. Multifunctional micelles are a combination of the different functionalities bought together to develop the ideal delivery platform. However, the basic architecture of modern micelles is getting more complex, which not only could create the reproducibility problem, but also high siRNA entrapment and better cellular uptake will be an issue. Such complexity could also become the hurdle in real-life clinical utilization, and finally, the approvals from the various regulatory bodies will be the challenge<sup>231</sup>.

#### 5.4. Polymer-based siRNA delivery

Until now, the unavailability of the proper delivery vehicle has restricted the clinical application of siRNA. siRNAs, which are the double-stranded negative charge molecules with hydrophilic characters, are relatively impermeable to the cell membrane. Chemical modifications to change the characteristics of the siRNA are required to cargo them to the cytosol. Such modifications could adversely affect the binding properties, and in some cases, siRNA could even irreversibly change to an inactive molecule. As discussed, various lipids and polymer-based delivery vehicles systems based on the nanotechnology platform were developed. Among them, the polymer-based delivery system received wider acceptance. Different gene-based products like protein, nucleic acids, peptides were delivered to the cells using polymer-based delivery systems.

We have already discussed the lipid-based strategies and the impressive research that took place to develop them into a potential delivery candidate. Polymers also have a potential role to play in the cytosolic delivery of proteins, DNA, and siRNA<sup>232-235</sup>. Various polymer compositions with different topology could be synthesized using techniques like atom transfer radical polymerization, reversible addition-fragmentation chain transfer polymerization, and ring-opening metathesis polymerization. At the same time, they can be readily derivatized by adding different functional groups to suit the applications. Moreover, the polymers with positive charge have developed a special interest in the delivery of siRNA. They not only form the reversible complex with the negatively charged RNA molecules but, but also facilitate the higher cellular uptake and endosomal escape. The stable reversible complex formation of siRNA with polymers is the challenge that needs to meet on a priority basis. Cationic polymers are already explored for their capability to carry the gene to the cell<sup>236-238</sup>. Due to the high negative charges on the siRNA, the cationic polymers bind and condense into the nanoparticles *via* ionic interactions. Even with the advancement in the polymers science, its use is restricted because of the limited number of binding sites available on the siRNA molecules. The limited interactions between the polymers and siRNA molecules lead to the formation of relatively unstable nanoparticles. This problem could be overcome with the utilization of hyperbranched polymers with large molecular weight and dendritic topology. Such polymers significantly enhance the transfection efficiency but at the cost of toxicity. For example, Yang et al.<sup>239</sup> reported a nanoparticle system composed of high molecular weight linear PEI condensed with DNA and coated by a shell of polyethyleneglycol-modified (PEGylated) low molecular weight linear PEI. Compared with the commercial delivery system, a 16,000-fold increase in the transfection efficiency was observed. Although the nanoparticles offer substantial advantages of higher transfection efficiency, linear PEI toxicity was observed. siRNA delivery using high molecular



weight polymers is still in the initial phase of development. Several attempts have been made to develop polymer with high transfection efficiency and lower toxicity<sup>240-242</sup>.

As discussed, intracellular delivery of the siRNA to the normal and cancer cell requires assistance from vectors. Vectors should not only be able to deliver the siRNA to the cytosol but also protect it from host nucleases. Recently, due to the vast interest in the siRNA therapeutic potential, a strong interest in the development of the non-toxic non-viral polymer-based vectors to improve the transfection efficiency was generated. Juanes et al.<sup>243</sup> very recently explored the potential of amphiphilic polyhydrazones and the degree of polymerization for the intracellular delivery of siRNA. They also demonstrated that this system could also be adopted for the complexation of mRNA.

PEI, which played a crucial role in the plasmid DNA delivery, is not considered very efficient for siRNA delivery. The lower efficiency of PEI to transfect siRNA is because of the shorter length of siRNA as compared with the DNA molecules. The electrostatic force of attraction between the negatively charged siRNA and PEI is also not sufficient to hold the complex together, which dissociates at the anionic cell surface<sup>244</sup>. Another major concern with the use of PEI is its toxicity which severely limited its use in nucleic acid delivery<sup>245</sup>. However, recently due to the availability of the linear and branched derivatives of PEI in a wide range of molecular weight, interest in its delivery potential has been reestablished. Such derivatives are the less toxic variation of PEI with better protection for siRNA from the nucleases. The toxicity associated with PEI has been controlled by incorporating low molecular weight PEI into other polymeric constructs<sup>246</sup>. Chemical modification of the PEI also helps to introduce the functionalities like targeted delivery, higher resistance against the nucleases, better endosomal escape, prolonged systemic circulation, and external and internal stimuli-responsive release of siRNA<sup>13,247-249</sup>. The most feasible approach to mitigating the PEI toxicity is through the introduction of the hydrophobic characters. This approach, however, is associated with the reduction in the overall positive charges on the PEI, which could affect the polyplexes formation with siRNA. The optimum balance between the hydrophobic characters and overall positive charges is essential for the success of PEI in siRNA delivery. The addition of the alkylcarboxyl groups to the branched PEI is found to impart the hydrophobicity, and carboxylation up to 20% was found to be associated with the better endosomal escape<sup>250</sup>. An increased in the length of the alkyl chain, which is used to enhance the hydrophobic character, has also been associated with the improved stability of the siRNA complex and reduced toxicity as compared with the PEI having a molecular weight of 25 kDa<sup>251,252</sup>.

Low molecular weight PEI, along with the low toxicity, also has low transfection efficiency. This issue was overcome by the introduction of disulfide bonds in the cross-linked PEI<sup>253-255</sup>. The optimized equilibrium between branch density and cleavable disulfide bond within PEI is found to be the crucial factor in achieving better siRNA delivery<sup>256</sup>. Kim et al.<sup>257</sup> combined low toxicity and better transfection efficiency by conjugating the hydrophobic lipid anchor, cholesterol chloroformate to the cationic head of low molecular weight branched PEI<sup>257</sup>. This complex was used to transfect the siRNA designed to inhibit the vascular endothelial growth factor in human prostate adenocarcinomas<sup>257</sup>. For targeted delivery of siRNA to inhibit dihydrofolate reductase enzyme, Biswal et al.<sup>258</sup> developed folate-conjugated PEI. The complex was used to inhibit the folate reductase in human epidermal carcinoma<sup>258</sup>.

Similarly, Yamaoka et al.<sup>259</sup> conjugated pullulan with PEI for liver targeting. siRNA was complexed with pullulan-containing PEI. Pullulan has a very high affinity towards the asialoglycoprotein receptor, highly expressed on the liver cells, ensuring the targeted delivery of siRNA. Similarly, galactose has a high affinity towards the asialoglycoprotein receptors, which was also used for the targeted delivery of siRNA molecules<sup>260,261</sup>. PEI derivatives were also studied for the stimuli-responsive release of siRNA. For example, Lee et al.<sup>262</sup> conjugated PEI with embedded magnetite nanocrystals to develop stimuli-responsive release of siRNA.

PLGA is another polymer that is widely used for siRNA delivery. It is a copolymer composed of glycolic acid and lactic acid linked through an ester bond. The ester bond undergoes hydrolysis to form the monomers back. The rate of hydrolysis depends upon and could vary with the ratio of monomers, total molecular weight, structure, and shape of the polymer. PLGAs having different proportions of monomers, molecular weight, structures, and shapes are developed commercially for various biomedical applications. Nanoparticles composed of PLGA have been widely screened for the delivery of drugs and gene-based products. PLGA has created huge interest as an alternative to viral-based delivery of siRNA<sup>263</sup>. They offer the advantage of small particle size, relatively non-toxic, and sustained release profile<sup>264</sup>. In general, nucleic acids are loaded into PLGA-based nanoparticles by encapsulating it inside the core or by adsorption *via* electrostatic force of attraction between the modified positively charged surface of PLGA and negatively charged siRNA molecules. PLGA nanoparticles have created huge interest in the delivery of therapeutics because of their high stability, higher endocytosis rate, targeting ability by conjugating them with the targeting ligands, and biodegradability. PLGA matrix can entrap siRNA to provide resistance against RNase activity, and it also imparts favorable colloidal stability to

the delivery formulation which facilitates safe and sustained, release profiles. For sustain release variation, degradation time of PLGA could be managed from days to years by varying the molecular weight and the ratio of its monomers<sup>256</sup>. The initial challenge in the loading of the negatively charged siRNA to the negatively charged PLGA nanoparticles is because there is no electrostatic interaction. Conjugation of the cationic moiety to the PLGA matrix could impart the stability and toxicity issues<sup>265</sup>. Such modification could also sometimes negatively affect the activity of siRNA. To overcome these flaws, Cun et al.<sup>266</sup> used a double emulsion solvent evaporation method to incorporate the siRNA in PLGA nanoparticles. This research group successfully incorporated the siRNA inside the PLGA nanoparticles without affecting its stability and activity<sup>266</sup>. Although this approach is successful for loading siRNA in PLGA nanoparticles without the use of cationic conjugated, it has limited application because of the low loading and encapsulation efficiency<sup>266</sup>. The low loading is attributed to the repulsion force between the phosphate backbone of siRNA and the anionic acid groups in PLGA polymers. Using a similar method, Cun et al.<sup>267</sup> also proposed various formulations of PLGA to load the siRNA molecules for therapeutic delivery. They optimized the formulations of PLGA by varying the siRNA load, PLGA concentration, ratio of monomers, water, and oil phase of the emulsion, and the amount of bovine serum albumin added to stabilize the emulsion. PLGA concentration was found to be critical in achieving the encapsulation efficiency of more than 70%. However, bovine serum albumin addition was found to enhance the encapsulation efficiency at lower PLGA concentration<sup>267</sup>. Despite of this outstanding character, with the lower electrostatic force of attraction with siRNA, and lack of endosomal escape, PLGA nanoparticles could not be efficiently used for the siRNA delivery. One of the most versatile strategies to overcome this issue is the use of polycations into PLGA-based nanoparticles. This strategy successfully enhanced the loading capacity of PLGA nanoparticles. To date, cationic compounds like DOTAP, PEI, or polyamine are conjugated with the PLGA nanoparticles at the cost of toxicity and high siRNA retardation. It is, therefore, essential to make less use of the cationic conjugated and employ the optimal formulation methods to achieve higher siRNA encapsulation and better release. Wang et al.<sup>268</sup> developed different nanoparticles for hepatitis B treatment with siRNA. The nanoparticles were composed of PLGA, methoxy poly (ethylene glycol)–poly (lactide) (mPEG–PLA), and chitosan and PEI for surface coating<sup>269</sup>. For the optimized transfection of siRNA, Andersen et al.<sup>270</sup> developed a method to conjugate the PLGA nanoparticle surface with polyethyleneimine by using a cetyl derivative. The formulation was used to silence the TNF $\alpha$  in J774.1 cells. In this method, sub-micron size particles were produced by employing the emulsion–diffusion method using benzyl alcohol. The silencing of

*STAT3* in the dendritic cells is the crucial approach for cancer immunotherapy. Alshamsan et al.<sup>271</sup> have successfully shown that *STAT3* inhibition in B16 murine melanoma by siRNA polyplexes of PEI-linked PGLA promotes B16 cell death. Incorporation of the siRNA in the PEI-linked PGLA nanoparticles reduces the toxicity associated with PEI and also enhances the cellular uptake<sup>272</sup>. Different *in vitro* transfection efficiency study showed that the ability of PEI-linked PGLA nanoparticles to transfects depends on its ratio and the cell types<sup>273</sup>. Risnayanti et al.<sup>274</sup> recently proposed PLGA nanoparticles as a delivery vehicle for MDR1 and BCL2 siRNA to MDR ovarian cancer cells. In this formulation, poly-L-lysine was used as a complexing agent for siRNA, which successfully inhibited the efflux of drugs from the ovarian cancer cells<sup>274</sup>. Patil et al.<sup>275</sup> similarly developed PLGA nanoparticles for siRNA delivery, where they used PEI to enhance the electrostatic attraction between the siRNA molecules and PLGA matrix. The nanoparticles were prepared by using the double emulsion solvent evaporation method.

Hasan et al.<sup>276</sup> developed a new method called “particle replication in nonwetting templates” for the preparation of PLGA nanoparticles coated with the lipids to deliver siRNA to the prostate cancer cells. This method was found to have the high encapsulation efficiency of siRNA in PLGA nanoparticles. Wang et al.<sup>277</sup> also developed PLGA–PEG cationic lipid nanoparticles by using the commonly employed double emulsion method. These nanoparticles have shown the very high encapsulation efficiency of around 90%, which effectively inhibits the target gene.

Chitosan, which is a linear polysaccharide made up of  $\beta$ -(1→4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit), has gained immense interest in the pharmaceutical industry. The characters like natural origin, abundance, non-immunogenicity, biocompatibility, and biodegradability have contributed immensely to its popularity for biological applications. It also possesses positive charges, which help to form the complex with the negatively charged siRNA. This character of chitosan makes it a useful non-viral vehicle for the siRNA delivery. D-Glucosamine residue, which has a  $pK_a$  value of about 6.2–7.0, gives weak basic character to the chitosan. At the pH below its  $pK_a$  value, protonation of the primary amines imparted cationic character to it. Such positively charge polymer forms polyplexes with DNA and siRNA, which pose a negatively charged phosphate backbone. Chitosan-mediated delivery of DNA is widely studied; however, its application for siRNA delivery is getting momentum in recent times<sup>278</sup>. Since the last decade, various formulations of chitosan are under the development for the siRNA delivery. For example, chitosan aspartate, chitosan glutamate, chitosan acetate, chitosan hydroxybenzotriazole, and chitosan hydrochloride were used to deliver siRNA to green

fluorescent protein-expressing HeLa cells<sup>279</sup>. Chitosan water solubility was found to be increased when a water-soluble vitamin called thiamine pyrophosphate conjugated with the amine group of chitosan through its phosphate group. Also, the other amine groups of thiamine pyrophosphate, particularly the thiazolium moiety, remain protonated at physiological pH, allowing electrostatic binding with the negatively charged siRNA molecules. This enhanced attraction with siRNA and water solubility helps to increase transfection efficiency<sup>280</sup>. In another approach to introduce the secondary and tertiary amines, imidazole acetic acid was conjugated to the chitosan. This modification substantially helped to enhance the water solubility and endosomal escape of siRNA<sup>281</sup>. Interpolyelectrolyte siRNA/chitosan complexes developed by Howard et al.<sup>282</sup> successfully overcame the issue of lower uptake and higher degradation of siRNA. A significant decrease in the enhanced green fluorescence protein-expressing epithelial cells in the bronchiole of mice *via* daily nasal administration of interpolyelectrolyte siRNA/chitosan complexes was observed<sup>282</sup>. As discussed earlier, calcium phosphate is an efficient siRNA delivery system but suffers due to the inconsistent particle size formation and transfection efficiencies. To overcome the issue, Choi et al.<sup>283</sup> developed the CaP nanocarrier system by adding cationic glutamine-conjugated oligochitosan, which significantly enhanced the transfection efficiency. For pulmonary gene therapy, Ni et al.<sup>284</sup> developed a pH-sensitive system composed of guanidinylated *O*-carboxymethyl chitosan and *N*-2-hydroxypropyltrimethyl ammonium chloride chitosan for the successful delivery of siRNA to the lungs. The siRNA against the survivin delivered using this system, was found to inhibit cell growth by 30% and induced cell apoptosis by around 20%<sup>284</sup>. Sun et al.<sup>285</sup> for efficient siRNA delivery developed poly(ethylene glycol)-modified chitosan carrier system. Improvement in the stability of siRNA, and better transfection efficiency of siRNA-loaded in poly(ethylene glycol)-modified chitosan nanoparticles in cancer cell line was observed<sup>285</sup>.

As discussed before, synthetic cationic polypeptides like PLL and PLA have also been widely studied for their gene delivery capabilities. However, these polypeptides are cytotoxic when used alone due to the very high cationic charges on them<sup>286</sup>. Several attempts were made to resolve this issue by combining them with hyaluronic acid and chitosan<sup>287,288</sup>. Plianwong et al.<sup>289</sup> reported an efficient and easy-to-prepare method to combine chitosan with PLA to deliver siRNA to the cancer cell (HeLa cells expressing enhanced green fluorescent protein). Low solubility in the physiological condition is another severe issue which has restricted widespread use of chitosan in the siRNA delivery. Hydroxybutyl chitosan, a derivative, soluble under the neutral condition, was used by Wan et al.<sup>290</sup> to target the tissue factor. The group used tissue factor targeting siRNA as a therapeutic tool for cardiovascular diseases.

Hydroxybutyl chitosan, in the future, has the potential to deliver the siRNA to target the cancer cells<sup>290</sup>. Arami et al.<sup>291</sup> reported the magnetic nanoparticles composed of polyethyleneglycol–lactate polymer, chitosan, and polyethyleneimine. The biocompatible nanoparticle was successfully used to deliver the siRNA to human breast cancer MCF-7 and leukemia K562 cells<sup>291</sup>. Shen et al.<sup>292</sup> reported a polymer-coated nanoparticle fabrication method for the siRNA delivery. The natural polyphenol (–)-epigallocatechin-3-*O*-gallate, which is a major compound found in green tea, was used to form the siRNA nanoparticles<sup>292</sup>. The polyphenol (–)-epigallocatechin-3-*O*-gallate could form strong electrostatic bonds with negatively charged compounds like DNA, RNA and proteins *via* hydrogen bonds<sup>293</sup>. The polyphenol (–)-epigallocatechin-3-*O*-gallate-siRNA complex once formed, was coated with the low-molecular-weight cationic polymer to develop the shell.<sup>294</sup> Shen et al.<sup>294</sup> also conjugated the polyphenols like phenol, catechol and pyrogallol with low molecular weight polymers to efficiently deliver the siRNA molecules to the cytosol.

Polymer-mediated siRNA delivery to the cancer cells has several benefits, for example, it offers chemical modifications to make soluble derivatives, ligand conjugation for targeted delivery, biocompatibility, conjugation with inorganic materials, which can address various barriers related with efficient siRNA delivery. The integration of multiple functionalities into polymeric siRNA delivery systems could have intense influences on biomedical research and the ability to transform the spectrum of the therapeutic field in curing cancer.

## 6. Challenges, prospects and future plans in the delivery of siRNA

### 6.1. Challenges

In the coming time, siRNA holds the massive potential to be used as a therapeutic tool for genetic disorders. It provides a high degree of gene selectivity, which is difficult to achieve with the current treatment options. Thus, with the RNA-based therapeutics, the targets which were previously inaccessible can now be targeted selectively. For example, protein-coding and non-coding mRNAs and premRNAs, which were initially thought to be undruggable, can now be targeted with the siRNAs.

Several approaches are under development for the siRNA delivery to cells, and few of them are under clinical investigation<sup>295</sup>. As the siRNAs carry the negative charge, they are hindered from entering through the hydrophobic cell membrane. The effective strategy to administer the siRNAs inside the cells

is through the endocytosis process. To be effective, siRNAs must exit out of the endosomes; otherwise, it could leave the cells *via* exocytosis process or may degrade by ribonuclease enzymes. Due to the off-site targeting, siRNA must be administered in the low dose, which prevents its optimum use. One of the most critical non-intended side effects is the innate immune system activation because of the immune motif in the siRNA sequence. Immune system activation motifs of siRNA could be identified by Toll-like receptors triggering the immune response along with the production of interferons ( $\alpha$  or  $\beta$ ) and inflammatory cytokines<sup>296</sup>.

Another major hurdle is the displacement of the natural siRNA from RISC meant for the normal physiological functions with the externally administered siRNA. In such cases, because of the partial binding of the siRNA, mRNA cleavage may not occur, but the cell could not carry out the normal cellular function<sup>297</sup>. Other factors that affect the effectiveness of the siRNA treatment include glomerular filtration, degradation by serum ribonucleases, endothelial barrier, and attack by immune cells<sup>297</sup>.

## 6.2. Prospects

The crucial aim of the research is the delivery of siRNA to the cancer cells after systemic administration. Leaky underdeveloped vasculature of growing tumors helps to uptake more nanoparticles inside the tumor *via* EPR. Still, only around 15% of the administered dose can accumulate in the tumor. Most of the lost treatment is linked to the nonspecific reticular endothelial system. For the uncharged compounds of molecular weight, less than 5000 Da is the uphill task. There are around 25 charged phosphodiester linkages forming the backbone of siRNA, which hinders the cellular uptake. On the other hand, nuclease enzymes of the blood cause the rapid degradation of siRNA, which further limits its bioavailability. Active transport *via* encapsulated ligand targeted nanocarriers offers the solution to this issue. PEGylated ligand targeted liposomal, or micelles are aimed to avoid the nonspecific reticular endothelial system clearance. These targeted nanocarriers exhibit better cellular uptake than the untargeted and, at the same time, protect the siRNA from the nucleases. Although siRNA has one specific mRNA target, reports of unintended silencing of the other genes having partial complementary regions causing severe side effects are available. Sometimes siRNA could also trigger the innate immune system to release pro-inflammatory cytokines. A variety of chemical modifications has been applied to the siRNA, which have tremendously improved the stability of siRNA in the blood and reduce off-site deposition. The chemical modification also hides the siRNA from the immune surveillance. Two of the most versatile

modification of siRNA is the fluorination and methylation at the 2'-position<sup>298</sup>. Both these modifications are found to be well tolerated throughout sense and antisense strands. Primarily these modifications are aimed at enhancing the half-life of siRNA in plasma by protecting it from the nucleases. At present, we do not need to enhance the potency of the siRNA through chemical modifications. Preserving the existing potency is sufficient for the therapeutic purpose. However, when 2'-O-Me and 2'F-RNA modification was done in the same siRNA, 500 fold increase in the potency was observed when compared with the unmodified siRNA<sup>299</sup>. A report of enhanced degradation of mRNA is available when enoxacin is linked with the siRNA<sup>300</sup>. In addition to this, immune activation is another severe issue related to siRNAs. Nonspecific immune response to the therapeutic siRNA may initiate the unwanted side effects. This issue could be resolved by downregulating the immunogenic characters of siRNA. Immune response towards the siRNA is a complex phenomenon, the details of which are available elsewhere. In short, siRNAs are identified by the toll-like receptors, protein kinase, and helicases, which lead to the induced secretion of the pro-inflammatory cytokines. Few nucleotide sequences have been linked to the immune activation; for example, 5'-GUCCUCAA-3' is the immune stimulatory sequence. In fact, the RNA sequence rich in U nucleotide is more easily identified by the immune system *via* TLR7 receptors<sup>301</sup>. Immunogenic stimulation could be substantially reduced by chemical modifications; for example, siRNA modified with 2'F-RNA, 2'-O-Me, and DNA residues have shown to have no effects on cytokines<sup>76</sup>.

Chemical modification of siRNA is a rapidly evolving field. Although considerable progress has been made in imparting the stability to the siRNA *via* chemical modifications, still they are sequence-dependent. With significant development in the lipid and polymer bases nanocarriers and simultaneous advancement in the chemical modification, the possibility of translation of siRNA from the lab to the clinics is very high.

## 7. Future plans

We have achieved tremendous success in siRNA studies; however, to make it a successful therapeutic agent, improvement in safety, delivery, pharmacokinetics, and pharmacodynamics is required. The future success of siRNA will depend on the successful development of the nanocarrier with better loading, transfection, and safety profile. The following section has discussed some of the immediate improvements for future applications.



### 7.1. Enhanced endosomal escape

siRNA inside the endosomes are the same as that of the outside of the cell. They have no therapeutic value unless they break the endosome and enter inside the cytosol. Chances of degradation at pH 4.5 of the lysosome are high if they do not escape from the endosome. Overall, endosomal escape is the major hurdle in the therapeutic application of siRNA. The present situation demands better external and internal stimulus-responsive polymers, which could release the drugs on exposure. Wei et al.<sup>302</sup> have developed an ultrasound-responsive polymersome based on PEO-*b*-poly(DEA-stat-MEMA) block copolymer to evaluate its intracellular anticancer drug delivery pathway and *in-vivo* systematic antitumor effect. This polymersome showed a favourable endosomal escape ability<sup>302</sup>. Puri et al.<sup>303</sup> recently studied sulfonated PEIs covalently linked to pyropheophorbide- $\alpha$  for photoactivation and modified amines (sulfo-pyro-PEI) for controlled endosomal escape. The results confirmed the on-demand release of the siRNA on photostimulation. Multivalent peptide-functionalized bioreducible polymers were developed for enhancing endosomal escape. It has been noted that the optimum number of hydrophobic side chains is essential for the micelle's assembly and cellular uptake, but an excess of it could lead to the less endosomal escape. Hence, in the future proper structural optimization of the polymers and construction of the nanoparticles are essentials to overcome the issue of the endosomal escape.

### 7.2. Conjugation with proteins and antibodies

Endosomal escape is an important event for the siRNA activity. The potency of the siRNA could be enhanced by increasing its serum half-life by conjugating with antibodies and proteins. One of them is the IgE (antibody), which is synthesized by the plasma cells. IgE, once synthesized, remains in the blood and tissues for weeks. IgE-siRNA complex is hypothesized to have a similar self-life in the blood<sup>304</sup>. However, the potency of siRNA under investigation was found to be lower than the unconjugated form. Another option for the conjugation could be albumin, which could not only assist the delivery to the cancer cells but also enhance the pharmacokinetic properties of the siRNA. Lower potency of the IgE-siRNA complex does not ensure that the future work could have a similar impact. We have to keep investigating the other options until we could considerably increase the efficiency of the siRNA along with pharmacokinetic characters<sup>305</sup>.

### 7.3. Tissue targeting and cellular uptake

One of the hurdles of cancer therapy is the off-site targeting. siRNA engulfed inside the nanoparticles are not only protected from the nucleases and rapid clearance from the body but, when targeting ligands linked to such nanoparticles, the targeted release of siRNA is possible. When siRNA is entrapped inside the nanoparticle, the particle of less than 150 nm can easily reach the hepatocytes, but the similar fenestrations are not available in the other tissues, thereby restricting the entry. Several ligands targeted nanocarriers like galactose-linked liposomes were proven to be useful in enhancing the drug activity at the liver site. PEG conjugation is another method to avoid macrophage identification. Tumor targeting based only on PEGylation and passive diffusion through EPR is not always suitable for different types of cancer. Therefore, to reduce the off-site accumulation and to deliver siRNA inside the cancer cells, facilitated or active diffusion is the better choice. Ligand-conjugated endocytosis mediating delivery of the siRNA to the target cells could eliminate the possibility of the side effects and, at the same time, increase the efficiency of the siRNA. In the future, facilitated and active transportation, external stimuli mediation (*e.g.*, magnetic field, ultrasonic waves, laser lights, sound, and light, etc.), and on-demand release of the siRNA needs to be explored further. For such approaches to be successful, smart stimuli responding polymers are required.

#### *7.4. Multifunctional approach*

Several hurdles need to be overcome to achieve the maximum potential of the therapeutic siRNA. The hurdles are endosomal escape, lower cellular uptake, rapid excretion, degradation by nucleases, and immune stimulation<sup>306</sup>. Combining all the solutions in one delivery system could lead to the development of the ideal carrier, which, however, is a difficult task. A multifunctional system that could connect most of the characters of the ideal delivery system could potentially replace the existing systems. The inclusion of the endosomal escape motifs in a multifunctional platform without altering the cellular uptake and potency of targeting ligand could enhance the overall performance of the system<sup>307</sup>. The addition of the targeting ligand could reduce the non-specific accumulation and, at the same time, could enhance the site-specific delivery. Chemical modification at the 2' position of RNA could protect the RNA molecules from nuclease degradation, and fusing lipids could enhance the cellular uptake. Combining all the motifs to get in one single device would increase the complexity of the delivery system. Hence, it is indispensable to study the overall physiochemical aspects of each component, how they complement each other's activity and, at the same time, perform their function independently<sup>308</sup>.

#### *7.5. Novel targets and ligands*

As discussed earlier, one of the biggest challenges in the therapeutic translation of the siRNA is the successful delivery to the cancer cells. This required the appropriate size of the nanoparticles conjugated with the ligands. Receptors for the targeting ligands are generally expressed on diseased cells. Such receptors assist in the endocytosis of the nanoparticles to which this ligand is linked. Several surface protein expression is enhanced in the disease condition, and the ligands for such proteins are identified. The ligands could be the antibodies, aptamers, cell-penetrating peptides, etc. Other than targeting the different types of cells, ligands for the endothelial cells of the different organs could be a useful tool to target the cancer of various organs. Identification of the ligand for the leucocyte, which in general is difficult to target, would be very useful in case of blood cancer and certain viral infections. In the future, transfection to a subset of leucocyte will be the challenge to meet. Very recently, CpG oligodeoxynucleotides, which binds to the TLR9 to initiate the innate immune response towards the foreign invention, was linked to the siRNA to target the B cells<sup>309</sup>. Similarly, an antibody against CD7 protein was used to target the siRNA to the T cells<sup>310</sup>. Similar to leucocytes, it is very difficult to deliver the siRNA using nanocarrier to the neurons. Identification of ligands for the neurons could be beneficial for the treatment of brain cancer, Alzheimer's, Parkinsonism, and infections like encephalitis. Rungta et al.<sup>311</sup> have developed the siRNA –lipid nanoparticle systems to deliver siRNA to the neurons. Recently, polyelectrolyte–gold nano assemblies were successfully used by Chaudhary et al.<sup>312</sup> to deliver the siRNA to the neuronal cells. Solanki et al.<sup>313</sup> in 2013 have developed a delivery platform known as nanotopography-mediated reverse uptake to deliver siRNA to the neural stem cells. A major breakthrough was achieved in crossing the BBB when Rabies virus glycoprotein was used as a targeting ligand to deliver the siRNA to the brain<sup>314</sup>. Even after the progress in the siRNA biology and delivery system, we have to keep looking for new targets for leukocytes and other cancers. The use and expansion of the protein database, and peptide and aptamer libraries could be useful for the siRNA delivery in the future.

#### *7.6.Reducing toxicity of lipid and polymer-carriers*

Lipid carriers offer several advantages to carry the drugs and gene products like siRNA. The distinct advantages include protection from nuclease-based degradation, site-specific targeting using targeting ligands, lower side effects, and better half-life of the drugs<sup>315</sup>. Liposomes prepared from lipids also have their disadvantages, which include a) large scaleup problems, b) low drug/siRNA entrapment efficiency, c) very poor long term storage stability, d) aggregation to form the bigger aggregates, e) licking of

water-soluble drugs in the blood, and f) toxicity of the lipid components. Toxicity could occur because of toxic lipids or its metabolites, particle size large enough to block the small blood capillaries, interaction with the blood components, etc. Toxicity due to the lipids-based carriers is mostly because of the charges they carry. To minimize the side effect, it is necessary to select the lipids favoring the small particle size and total compositions, which support fewer overall charges on the surface. For example, the most commonly used lipid-based carriers are cationic liposomes, which can interact with several proteins, lipoproteins, and collagen leading to the formation of the aggregates or premature release of the drugs leading to the systematic toxicity<sup>316</sup>. Cationic lipids have proven to have hepatic toxicity; they inhibit the protein kinase c activity and could induce lung inflammations<sup>317</sup>. Cationic liposomes were also found to have a toxic effect on macrophages on short term exposure<sup>318</sup>. Conjugating the lipid carrier to the targeting ligand could help to reduce the side effects of the lipids. In the end, to overcome the issue of nanoparticle toxicity, it is advisable to access the key characters which contribute to the toxicity adequately, which include: a) proper physiochemical characterization, b) surface property characterization, c) proper assessment of *in vitro* toxicity studies, d) reactive oxygen species assays, e) toxicity studies in proper animal models, and f) genotoxicity studies. In the future, masking of the nanoparticle surface with various biocompatible and hydrophilic polymers would be the focus of the research to reduce the adverse effects. Agents like PEG, polyethylene oxide, polyoxamer, poloxamine, and polysorbate 80 were already under investigation for their role in offering the biocompatibility to the lipid nanocarriers<sup>319</sup>. Nowadays, the need for a more efficient surface masking agent is very high, and there could not be better agents than the natural polymers. Going forward, the future of lipid-based carriers in siRNA delivery to the cancer cells is bright.

## 8. Conclusions

Once inside the cell, siRNAs form the RISC and subsequently destruct the mRNA. However, due to the polyanionic charges, siRNAs are unable to cross the lipid membrane, making the suitable delivery vehicle an urgent requirement for siRNA-based therapies. Cationic lipid base nanoparticles containing ionizable amino lipids are the promising vehicle for the negatively charged nucleic acids. Interaction of amino lipids with the endosomal membrane allows the better endosomal escape and bioavailability. Despite being the favourable candidate for drug delivery, serious side effects have restricted their use. Along with the development of novel delivery vehicles, the development of the new lipids with no side effects is inevitable. Scientists are paying more attention to the hard-to-transfect leucocytes by developing specialized lipids.

So far, many different types of cationic and polymeric nanocarrier delivery systems are developed. In this review, we have discussed the popular siRNA delivery systems and their potential in cancer treatment. But we still have a lot of challenges to deal with before they can become the trusted delivery systems. The journey of cationic nanocarriers from untargeted to target to LPD and LCP nanocarriers with distinct advantages of better exosomal escape and cellular uptakes is phenomenal. The literature studies revealed that the PEGylation is crucial as it helps the nanoparticle to hide from the macrophages and enhances the blood circulation time. Modification of the siRNA is also critical to protect the siRNA from the nuclease-based degradation. Despite the creation of several nanocarriers with different functionalities, the final availability of siRNA for mRNA destruction is very less. This indicates that there is a vast scope in enhancing the ability of the nanocarriers. Strategies for the endosomal escape, cell and tissue targeting, and development of the novel biomaterials are crucial for the translation of siRNA from the lab to the patients on the bed.

### **Acknowledgments**

Nitin Bharat Charbe is the recipient of FONDECYT POSTDOCTORADO Fellowship (Comisión Nacional de Investigación Científica y Tecnológica, CONICYT, POSTDOCTORADO Fellowship, Chile) (PROYECTO N° 3180250).

### **Authors contributions**

Nitin Bharat Charbe and Flavia C Zocconi conceptualized and wrote the manuscript. Nikhil D Amnerkar, Murtaza Tambuwala, Alaa A A Aljabali, and Saurabh Satija designed the figures. Kamal Dua, Saurabh C Khadse, Dinesh Kumar Chellappan, Rajendran Satheeshkumar and B Ramesh edited the manuscript. Meenu Metha, Poonam Negi, Garima Shrivastava, Hamid A Bakshi, Gaurav Gupta checked the figures and formatted the tables. All authors have read and approved the final manuscript.

### **Conflict of interests**

The authors have no conflicts of interest to declare.

### **References**

1. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences.

*Adv Drug Deliv Rev* 2009;**61**:746–59.

2. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. *Cancer Discov* 2013;**3**:406–17.
3. Tang G. siRNA and miRNA: an insight into RISCs. *Trends Biochem Sci* 2005;**30**:106–14.
4. Li Z, Rana TM. Molecular mechanisms of RNA-triggered gene silencing machineries. *Acc Chem Res* 2012;**45**:1122–31.
5. Nykänen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. *Cell* 2001;**107**:309–21.
6. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. *Science* 2002;**297**:2056–60.
7. Oh YK, Park TG. siRNA delivery systems for cancer treatment. *Adv Drug Deliv Rev* 2009;**61**:850–62.
8. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 2001;**411**:494–8.
9. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. *Nature* 2004;**432**:173–8.
10. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. *Nat Rev Drug Discov* 2007;**6**:443–53.
11. Ye QF, Zhang YC, Peng XQ, Long Z, Ming YZ, He LY. Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. *Oncol Lett* 2012;**3**:879–84.
12. Bai Z, Zhang Z, Qu X, Han W, Ma X. Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1. *Oncol Lett* 2012;**3**:135–40.
13. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. *Nucleic Acids Res*

- 2004;**32**:1–10.
14. Perez J, Bardin C, Rigal C, Anthony B, Rousseau R, Dutour A. Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines. *Anticancer Res* 2011;**31**:2813–20.
  15. Yamazaki H, Iwano T, Otsuka S, Kagawa Y, Hoshino Y, Hosoya K, et al. SiRNA knockdown of the DEK nuclear protein mRNA enhances apoptosis and chemosensitivity of canine transitional cell carcinoma cells. *Vet J* 2015;**204**:60–5.
  16. Liu WS, Yan HJ, Qin RY, Tian R, Wang M, Jiang JX, et al. SiRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. *Dig Dis Sci* 2009;**54**:89–96.
  17. Jafarlou M, Shanehbandi D, Dehghan P, Mansoori B, Othman F, Baradaran B. Enhancement of chemosensitivity by simultaneously silencing of *Mcl-1* and Survivin genes using small interfering RNA in human myelomonocytic leukaemia. *Artif Cells, Nanomedicine Biotechnol* 2018;**46**:1792–8.
  18. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. *Oncogene* 2004;**23**:1539–48.
  19. Schmitz JC, Chen TM, Chu E. Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. *Cancer Res* 2004;**64**:1431–5.
  20. Chung DC, Long LT, Son HN, Bao LT, Si DM, Van Dong L. Downregulation of vascular endothelial growth factor enhances chemosensitivity by induction of apoptosis in hepatocellular carcinoma cells. *Cell J* 2015;**17**:273–87.
  21. Liu T, Wu X, Li Y, Lu W, Zheng F, Zhang C, et al. RBFOX3 regulates the chemosensitivity of cancer cells to 5-fluorouracil via the PI3K/AKT, EMT and cytochrome-c/caspase pathways. *Cell Physiol Biochem* 2018;**46**:1365–80.
  22. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. *J Am Coll Surg* 2004;**198**:953–9.

23. Nozawa H, Tadakuma T, Ono T, Sato M, Hiroi S, Masumoto K, et al. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. *Cancer Sci* 2006;**97**:1115–24.
24. Wang R, Dong K, Lin F, Wang X, Gao P, Wei SH, et al. Inhibiting proliferation and enhancing chemosensitivity to taxanes in osteosarcoma cells by RNA interference-mediated downregulation of stathmin expression. *Mol Med* 2007;**13**:567–75.
25. Liu C, Zhao G, Liu J, Ma N, Chivukula P, Perelman L, et al. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. *J Control Release* 2009;**140**:277–83.
26. Shen J, Liu J, Long Y, Miao Y, Su M, Zhang Q, et al. Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. *Acta Biochim Biophys Sin (Shanghai)* 2009;**41**:223–30.
27. Kim M, Lee S, Park WH, Suh DH, Kim K, Kim YB, et al. Silencing *Bmi1* expression suppresses cancer stemness and enhances chemosensitivity in endometrial cancer cells. *Biomed Pharmacother* 2018;**108**:584–9.
28. Yue B, Ma JF, Yao G, Yang MD, Cheng H, Liu GY. Knockdown of neuropilin-1 suppresses invasion, angiogenesis, and increases the chemosensitivity to doxorubicin in osteosarcoma cells—an *in vitro* study. *Eur Rev Med Pharmacol Sci* 2014;**18**:1735–41.
29. Zhang YJ, Li AJ, Han Y, Yin L, Lin M Bin. Inhibition of Girdin enhances chemosensitivity of colorectal cancer cells to oxaliplatin. *World J Gastroenterol* 2014;**20**:8229–36.
30. Zheng S, Wang X, Weng YH, Jin X, Ji JL, Guo L, et al. siRNA knockdown of RRM2 effectively suppressed pancreatic tumor growth alone or synergistically with doxorubicin. *Mol Ther-Nucleic Acids* 2018;**12**:805–16.
31. Yang L, Kang WK. The effect of HIF-1 $\alpha$  siRNA on growth and chemosensitivity of Mia-paca cell line. *Yonsei Med J* 2008;**49**:295–300.
32. Shervington A, Patel R. Silencing DNA methyltransferase (DNMT) enhances glioma chemosensitivity. *Oligonucleotides* 2008;**18**:365–74.



33. Zhang J, Wang LS, Ye SL, Luo P, Wang BL. Blockage of tropomyosin receptor kinase a (TrkA) enhances chemo-sensitivity in breast cancer cells and inhibits metastasis *in vivo*. *Int J Clin Exp Med* 2015;**8**:634–41.
34. Wang Y, Xiang J, Wang J, Ji Y. Downregulation of TGF- $\beta$ 1 suppressed proliferation and increased chemosensitivity of ovarian cancer cells by promoting BRCA1/Smad3 signaling. *Biol Res* 2018;**51**:1–7.
35. Yu C, Zhang X, Sun G, Guo X, Li H, You Y, et al. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. *J Cell Mol Med* 2008;**12**:2334–49.
36. Li PC, Tu MJ, Ho PY, Jilek JL, Duan Z, Zhang QY, et al. Bioengineered NRF2–siRNA is effective to interfere with NRF2 pathways and improve chemosensitivity of human cancer cells. *Drug Metab Dispos* 2018;**46**:2–10.
37. Liu W, Zhu F, Jiang Y, Sun D, Yang B, Yan H. siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells. *Oncol Rep* 2013;**29**:1183–8.
38. Li X, Pei B, Wang H, Tang C, Zhu W, Jin F. Effect of AQP-5 silencing by siRNA interference on chemosensitivity of breast cancer cells. *Onco Targets Ther* 2018;**11**:3359–68.
39. Guo K, Song W, Gong Y, Hu S, Zhong W, Qiu W. Down-regulation of survivin expression by siRNA suppresses proliferation and enhances chemosensitivity in human pancreatic cancer cell line Panc-1. *Proceedings-2015 7th International Conference on Measuring Technology and Mechatronics Automation, Nanchang, China ICMTMA 2015*, 2015, bl 400–2.
40. Shen J, Wang Q, Hu Q, Li Y, Tang G, Chu PK. Restoration of chemosensitivity by multifunctional micelles mediated by P-gp siRNA to reverse MDR. *Biomaterials* 2014;**35**:8621–34.
41. Yang H, Fu JH, Hu Y, Huang WZ, Zheng B, Wang G, et al. Influence of SiRNA targeting survivin on chemosensitivity of H460/cDDP lung cancer cells. *J Int Med Res* 2008;**36**:734–47.
42. Ide H, Kikuchi E, Hasegawa M, Kozakai N, Kosaka T, Miyajima A, et al. Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma. *BMC Cancer* 2012;**12**:420.

43. Radia AM, Yaser AM, Ma X, Zhang J, Yang C, Dong Q, et al. Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines. *Int J Mol Sci* 2013;**14**:7959–78.
44. Morgan-Lappe S, Woods KW, Li Q, Anderson MG, Schurdak ME, Luo Y, et al. RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitors. *Oncogene* 2006;**25**:1340–8.
45. Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL, Cooke MP. Identification of modulators of TRAIL-induced apoptosis *via* RNAi-based phenotypic screening. *Mol Cell* 2003;**12**:627–37.
46. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. *Nat Cell Biol* 2005;**7**:591–600.
47. Futami T, Miyagishi M, Taira K. Identification of a network involved in thapsigargin-induced apoptosis using a library of small interfering RNA expression vectors. *J Biol Chem* 2005;**280**:826–31.
48. Brummelkamp TR, Nijman SMB, Dirac AMG, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF- $\kappa$ B. *Nature* 2003;**424**:797–801.
49. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. *Nature* 2004;**428**:431–7.
50. Kittler R, Putz G, Pelletier L, Poser I, Heninger AK, Drechsel D, et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division. *Nature* 2004;**432**:1036–40.
51. Song JJ, Smith SK, Hannon GJ, Joshua-Tor L. Crystal structure of argonaute and its implications for RISC slicer activity. *Science* 2004;**305**:1434–7.
52. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. *RNA* 2003;**9**:1034–48.

53. Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. *Biomaterials* 2014;**35**:3840–50.
54. Xu C fei, Wang J. Delivery systems for siRNA drug development in cancer therapy. *Asian J Pharm Sci* 2015;**10**:1–12.
55. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. *J Mol Biol* 1964;**8**:660–8.
56. Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. *J Control Release* 2009;**137**:234–40.
57. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. *Proc Natl Acad Sci U S A* 1987;**84**:7413–7.
58. Omidy Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtari S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. *J Drug Target* 2003;**11**:311–23.
59. Yu W, Pirolo KF, Yu B, Rait A, Xiang L, Huang W, et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. *Nucleic Acids Res* 2004;**32**:1–10.
60. Pirolo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R, et al. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. *Hum Gene Ther* 2006;**17**:117–24.
61. Lin Q, Chen J, Zhang Z, Zheng G. Lipid-based nanoparticles in the systemic delivery of siRNA. *Nanomedicine* 2014;**9**:105–20.
62. Kedmi R, Ben-Arie N, Peer D. The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation. *Biomaterials* 2010;**31**:6867–75.
63. Wasungu L, Hoekstra D. Cationic lipids, lipoplexes and intracellular delivery of genes. *J Control Release* 2006;**116**:255–64.
64. Li SD, Chen YC, Hackett MJ, Huang L. Tumor-targeted delivery of siRNA by self-assembled

- nanoparticles. *Mol Ther* 2008;**16**:163–9.
65. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, et al. A novel siRNA–lipoplex technology for RNA interference in the mouse vascular endothelium. *Gene Ther* 2006;**13**:1222–34.
66. Dana H, Chalbatani GM, Mahmoodzadeh H, Karimloo R, Rezaiean O, Moradzadeh A, et al. Molecular mechanisms and biological functions of siRNA. *Int J Biomed Sci* 2017;**13**:48–57.
67. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, et al. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. *Nat Commun* 2014;**5**:1–12.
68. Gomes-Da-Silva LC, Fonseca NA, Moura V, Pedroso De Lima MC, Simões S, Moreira JN. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. *Acc Chem Res* 2012;**45**:1163–71.
69. Buyens K, De Smedt SC, Braeckmans K, Demeester J, Peeters L, Van Grunsven LA, et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. *J Control Release* 2012;**158**:362–70.
70. Yagi N, Manabe I, Tottori T, Ishihara A, Ogata F, Jong HK, et al. A nanoparticle system specifically designed to deliver short interfering RNA inhibits tumor growth *in vivo*. *Cancer Res* 2009;**69**:6531–8.
71. Carmona S, Jorgensen MR, Kolli S, Crowther C, Salazar FH, Marion PL, et al. Controlling HBV replication *in vivo* by intravenous administration of triggered PEGylated siRNA-nanoparticles. *Mol Pharm* 2009;**6**:706–17.
72. Hatakeyama H, Akita H, Ito E, Hayashi Y, Oishi M, Nagasaki Y, et al. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG–lipid. *Biomaterials* 2011;**32**:4306–16.
73. Chono S, Li SD, Conwell CC, Huang L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. *J Control Release* 2008;**131**:64–9.
74. Yang XZ, Dou S, Wang YC, Long HY, Xiong MH, Mao CQ, et al. Single-step assembly of

- cationic lipid–polymer hybrid nanoparticles for systemic delivery of siRNA. *ACS Nano* 2012;**6**:4955–65.
75. Zhang Y, Li H, Sun J, Gao W, Liu W, Li B, et al. DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. *Int J Pharm* 2010;**390**:198–207.
76. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent *in vivo* anti-HBV activity of chemically modified siRNAs. *Nat Biotechnol* 2005;**23**:1002–7.
77. Zimmermann TS, Lee ACH, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. *Nature* 2006;**441**:111–4.
78. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. *J Clin Invest* 2009;**119**:661–73.
79. De Antonellis P, Liguori L, Falanga A, Carotenuto M, Ferrucci V, Andolfo I, et al. MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines. *Naunyn Schmiedebergs Arch Pharmacol* 2013;**386**:287–302.
80. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. *Lancet* 2010;**375**:1896–905
81. He W, Bennett MJ, Luistro L, Carvajal D, Nevins T, Smith M, et al. Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide *in vivo* delivery capability. *Mol Ther* 2014;**22**:359–70.
82. Jia Z, Gong Y, Pi Y, Liu X, Gao L, Kang L, et al. PPB Peptide-mediated siRNA-loaded stable nucleic acid lipid nanoparticles on targeting therapy of hepatic fibrosis. *Mol Pharm* 2018;**15**:53–62.
83. Mills KA, Quinn JM, Roach ST, Palisoul M, Nguyen M, Noia H, et al. p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts. *Sci Rep* 2019;**9**:1–10.

84. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B, et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. *Cancer Res* 2008;**68**:9788–98.
85. Heidel JD, Schluep T. Cyclodextrin-containing polymers: versatile platforms of drug delivery materials. *J Drug Deliv* 2012;**2012**:1–17.
86. Davis ME, Brewster ME. Cyclodextrin-based pharmaceuticals: past, present and future. *Nat Rev Drug Discov* 2004;**3**:1023–35.
87. Stella VJ, Rao VM, Zannou EA, Zia V. Mechanisms of drug release from cyclodextrin complexes. *Adv Drug Deliv Rev* 1999;**36**:3–16.
88. Freeman DJ, Niven RW. The influence of sodium glycocholate and other additives on the *in vivo* transfection of plasmid DNA in the lungs. *Pharm Res* 1996;**13**:202–9.
89. Gonzalez H, Hwang SJ, Davis ME. New class of polymers for the delivery of macromolecular therapeutics. *Bioconjug Chem* 1999;**10**:1068–74
90. Suzie HP, Davis ME. Development of a nonviral gene delivery vehicle for systemic application. *Bioconjug Chem* 2002;**13**:630–9.
91. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. *Cancer Res* 2005;**65**:8984–92.
92. Bellocq NC, Pun SH, Jensen GS, Davis ME. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. *Bioconjug Chem* 2003;**14**:1122–32.
93. Mellet CO, Fernández JMG, Benito JM. Cyclodextrin-based gene delivery systems. *Chem Soc Rev* 2011;**40**:1586–608.
94. Heidel JD, Yu Z, Liu JYC, Rele SM, Liang Y, Zeidan RK, et al. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. *Proc Natl Acad Sci U S A* 2007;**104**:5715–21.
95. Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans.

*Proc Natl Acad Sci U S A* 1993;**90**:11307–11.

96. Caplen NJ, Alton EFW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. *Nat Med* 1995;**1**:39–46.
97. Farhood H, Serbina N, Huang L. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. *Biochim Biophys Acta* 1995;**1235**:289–95.
98. Maitani Y, Igarashi S, Sato M, Hattori Y. Cationic liposome (DC-Chol/DOPE = 1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression. *Int J Pharm* 2007;**342**:33–9.
99. Dass CR, Choong PFM. Selective gene delivery for cancer therapy using cationic liposomes: *in vivo* proof of applicability. *J Control Release* 2006;**113**:155–63.
100. Oupicky D, Ogris M, Howard KA, Dash PR, Ulbrich K, Seymour LW. Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. *Mol Ther* 2002;**5**:463–72.
101. Lee J, Ahn HJ. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery carrier for ovarian cancer therapy. *Biochem Biophys Res Commun* 2018;**503**:1716–22.
102. Liu X, Madhankumar AB, Slagle-Webb B, Sheehan JM, Surguladze N, Connor JR. Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents. *Cancer Res* 2011;**71**:2240–9.
103. Seraj S, Lee J, Ahn HJ. Systemic delivery of Eg5 shRNA-expressing plasmids using PEGylated DC-Chol/DOPE cationic liposome: long-term silencing and anticancer effects *in vivo*. *Biochem Pharmacol* 2019;**166**:192–202.
104. Tseng WC, Tang CH, Fang TY, Su LY. Using disaccharides to enhance *in vitro* and *in vivo* transgene expression mediated by a lipid-based gene delivery system. *J Gene Med* 2007;**9**:659–67.
105. Yang S ye, Zheng Y, Chen J yin, Zhang Q yang, Zhao D, Han D en, et al. Comprehensive study

- of cationic liposomes composed of DC-Chol and cholesterol with different mole ratios for gene transfection. *Colloids Surfaces B Biointerfaces* 2013;**101**:6–13.
106. Bennett MJ, Nantz MH, Balasubramaniam RP, Gruenert DC, Malone RW. Cholesterol enhances cationic liposome-mediated DNA transfection of human respiratory epithelial cells. *Biosci Rep* 1995;**15**:47–53.
107. Chen Y, Sun J, Lu Y, Tao C, Huang J, Zhang H, et al. Complexes containing cationic and anionic pH-sensitive liposomes: comparative study of factors influencing plasmid DNA gene delivery to tumors. *Int J Nanomedicine* 2013;**8**:1573–93.
108. Nchinda G, Überla K, Zschörnig O. Characterization of cationic lipid DNA transfection complexes differing in susceptibility to serum inhibition. *BMC Biotechnol* 2002;**2**:1–10.
109. Kisoon N, Ariatti M, Moodley T. A novel cationic cholesterol derivative, its formulation into liposomes, and the efficient transfection of the transformed human cell lines HepG2 and HeLa. *Drug Deliv J Deliv Target Ther Agents* 2002;**9**:161–7.
110. Hattori Y, Nakamura M, Takeuchi N, Tamaki K, Shimizu S, Yoshiike Y, et al. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex. *J Drug Target* 2019;**27**:217–27.
111. Lechanteur A, Sanna V, Duchemin A, Evrard B, Mottet D, Piel G. Cationic liposomes carrying siRNA: impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape. *Nanomaterials* 2018;**8**:1–12.
112. Lechanteur A, Furst T, Evrard B, Delvenne P, Hubert P, Piel G. PEGylation of lipoplexes: the right balance between cytotoxicity and siRNA effectiveness. *Eur J Pharm Sci* 2016;**93**:493–503.
113. Behr JP, Demeneix B, Loeffler JP, Perez-Mutul J. Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. *Proc Natl Acad Sci U S A* 1989;**86**:6982–6.
114. San H, Yang ZY, Pompili VJ, Jaffe ML, Plautz GE, Xu L, et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. *Hum Gene Ther* 1993;**4**:781–8.
115. Wagner E, Cotten M, Foisner R, Birnstiel ML. Transferrin–polycation–DNA complexes: the



- effect of polycations on the structure of the complex and DNA delivery to cells. *Proc Natl Acad Sci U S A* 1991;**88**:4255–9.
116. Gao X, Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. *Biochemistry* 1996;**35**:1027–36.
117. Gao J, Chen H, Yu Y, Song J, Song H, Su X, et al. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA. *Biomaterials* 2013;**34**:10084–98.
118. Li SD, Chono S, Huang L. Efficient oncogene silencing and metastasis inhibition *via* systemic delivery of siRNA. *Mol Ther* 2008;**16**:942–6.
119. Li SD, Huang L. Surface-modified LPD nanoparticles for tumor targeting. *Ann N Y Acad Sci* 2006;**1082**:1–8.
120. Chen Y, Huang L. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. *Expert Opin Drug Deliv* 2008;**5**:1301–11.
121. Chen Y, Wu JJ, Huang L. Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. *Mol Ther* 2010;**18**:828–34.
122. Chen Y, Bathula SR, Yang Q, Huang L. Targeted nanoparticles deliver siRNA to melanoma. *J Invest Dermatol* 2010;**130**:2790–8.
123. Deng L, Zhang Y, Ma L, Jing X, Ke X, Lian J, et al. Comparison of anti-EGFR-Fab' conjugated immunoliposomes modified with two different conjugation linkers for siRNA delivery in SMMC-7721 cells. *Int J Nanomedicine* 2013;**8**:3271–83.
124. Chen Y, Sen J, Bathula SR, Yang Q, Fittipaldi R, Huang L. Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. *Mol Pharm* 2009;**6**:696–705.
125. Li F, Zhu Z, Xue M, He W, Zhang T, Feng L, et al. SiRNA-based breast cancer therapy by suppressing 17 $\beta$ -hydroxysteroid dehydrogenase type 1 in an optimized xenograft cell and molecular biology model *in vivo*. *Drug Des Devel Ther* 2019;**13**:757–66.
126. Hu Y, Singh R, Deng Z, Mintz A, Hsu W. Liposome-protamine-DNA nanoparticle-mediated delivery of short hairpin RNA targeting brachyury inhibits chordoma cell growth. *J Biomed*

- Nanotechnol* 2016;**12**:1952–61.
127. Jalali SA, Sankian M, Tavakkol-Afshari J, Jaafari MR. Induction of tumor-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. *Nanomedicine Nanotechnology, Biol Med* 2012;**8**:692–701.
  128. Zhao Y, Wang W, Guo S, Wang Y, Miao L, Xiong Y, et al. PolyMetformin combines carrier and anticancer activities for *in vivo* siRNA delivery. *Nat Commun* 2016;**7**:1–9.
  129. Gao J, Liu W, Xia Y, Li W, Sun J, Chen H, et al. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. *Biomaterials* 2011;**32**:3459–70.
  130. Li J, Chen YC, Tseng YC, Mozumdar S, Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. *J Control Release* 2010;**142**:416–21.
  131. Huang JL, Chen HZ, Gao XL. Lipid-coated calcium phosphate nanoparticle and beyond: a versatile platform for drug delivery. *J Drug Target* 2018;**26**:398–406.
  132. Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. *Expert Rev Mol Diagn* 2005;**5**:893–905.
  133. Sokolova V V, Radtke I, Heumann R, Epple M. Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. *Biomaterials* 2006;**27**:3147–53.
  134. Liu T, Tang A, Zhang G, Chen Y, Zhang J, Peng S, et al. Calcium phosphate nanoparticles as a novel nonviral vector for efficient transfection of DNA in cancer gene therapy. *Cancer Biother Radiopharm* 2005;**20**:141–9.
  135. Zhou C, Yu B, Yang X, Huo T, Lee LJ, Barth RF, et al. Lipid-coated nano-calcium-phosphate (LNCP) for gene delivery. *Int J Pharm* 2010;**392**:201–8.
  136. Wang X, Zhang M, Zhang L, Li L, Li S, Wang C, et al. Designed Synthesis of lipid-coated polyacrylic acid/calcium phosphate nanoparticles as dual pH-responsive drug-delivery vehicles for cancer chemotherapy. *Chem - A Eur J* 2017;**23**:6586–95.
  137. Tseng YC, Xu Z, Guley K, Yuan H, Huang L. Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. *Biomaterials*

- 2014;**35**:4688–98.
138. Wang M, Thanou M. Targeting nanoparticles to cancer. *Pharmacol Res* 2010;**62**:90–9.
139. Lee N, Choi SH, Hyeon T. Nano-sized CT contrast agents. *Adv Mater* 2013;**25**:2641–60.
140. Curry T, Kopelman R, Shilo M, Popovtzer R. Multifunctional theranostic gold nanoparticles for targeted CT imaging and photothermal therapy. *Contrast Media Mol Imaging* 2014;**9**:53–61.
141. Goldman LW. Principles of CT: radiation dose and image quality. *J Nucl Med Technol* 2007;**35**:213–25.
142. Zhu L, Torchilin VP. Stimulus-responsive nanopreparations for tumor targeting. *Integr Biol (Camb)* 2013;**5**:96–107.
143. Kreuter J. Nanoparticles and microparticles for drug and vaccine delivery. *J Anat* 1996;**189**:503–5.
144. Amendola V, Pilot R, Frasconi M, Maragò OM, Iatì MA. Surface plasmon resonance in gold nanoparticles: a review. *J Phys Condens Matter* 2017;**29**:1–48.
145. Kong FY, Zhang JW, Li RF, Wang ZX, Wang WJ, Wang W. Unique roles of gold nanoparticles in drug delivery, targeting and imaging applications. *Molecules* 2017;**22**:1–13.
146. Prusty K, Swain SK. Nano silver decorated polyacrylamide/dextran nanohydrogels hybrid composites for drug delivery applications. *Mater Sci Eng C* 2018;**85**:130–41.
147. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. *Mol Pharm* 2005;**2**:194–205.
148. Ngamcherdtrakul W, Morry J, Gu S, Castro DJ, Goodyear SM, Sangvanich T, et al. Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2<sup>+</sup> breast cancer. *Adv Funct Mater* 2015;**25**:2646–59.
149. Lee JS, Green JJ, Love KT, Sunshine J, Langer R, Anderson DG. Gold, poly( $\beta$ -amino ester) nanoparticles for small interfering RNA delivery. *Nano Lett* 2009;**9**:2402–6.
150. Kango S, Kalia S, Celli A, Njuguna J, Habibi Y, Kumar R. Surface modification of inorganic nanoparticles for development of organic-inorganic nanocomposites—a review. *Prog Polym Sci*

- 2013;**38**:1232–61.
151. Sperling RA, Parak WJ. Surface modification, functionalization and bioconjugation of colloidal Inorganic nanoparticles. *Philos Trans R Soc A Math Phys Eng Sci* 2010;**368**:1333–83. Doi: 10.1098/rsta.2009.0273.
  152. Roca M, Haes AJ. Probing cells with noble metal nanoparticle aggregates. *Nanomedicine* 2008;**3**:555–65.
  153. Vilela D, González MC, Escarpa A. Sensing colorimetric approaches based on gold and silver nanoparticles aggregation: chemical creativity behind the assay. A review. *Anal Chim Acta* 2012;**751**:24–43.
  154. Ding Y, Jiang Z, Saha K, Kim CS, Kim ST, Landis RF, et al. Gold nanoparticles for nucleic acid delivery. *Mol Ther* 2014;**22**:1075–83.
  155. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AKR, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. *Science* 2006;**312**:1027–30.
  156. Seferos DS, Prigodich AE, Giljohann DA, Patel PC, Mirkin CA. Polyvalent DNA nanoparticle conjugates stabilize nucleic acids. *Nano Lett* 2009;**9**:308–11.
  157. Jin R, Wu G, Li Z, Mirkin CA, Schatz GC. What controls the melting properties of DNA-linked gold nanoparticle assemblies?. *J Am Chem Soc* 2003;**125**:1643–54.
  158. Lytton-Jean AKR, Mirkin CA. A thermodynamic investigation into the binding properties of DNA functionalized gold nanoparticle probes and molecular fluorophore probes. *J Am Chem Soc* 2005;**127**:12754–5.
  159. Thaxton CS, Hill HD, Georganopoulou DG, Stoeva SI, Mirkin CA. A bio-bar-code assay based upon dithiothreitol-induced oligonucleotide release. *Anal Chem* 2005;**77**:8174–8.
  160. Giljohann DA, Seferos DS, Patel PC, Millstone JE, Rosi NL, Mirkin CA. Oligonucleotide loading determines cellular uptake of DNA-modified gold nanoparticles. *Nano Lett* 2007;**7**:3818–21.
  161. Hurst SJ, Lytton-Jean AKR, Mirkin CA. Maximizing DNA loading on a range of gold nanoparticle sizes. *Anal Chem* 2006;**78**:8313–8.
  162. Lee JS, Seferos DS, Giljohann DA, Mirkin CA. Thermodynamically controlled separation of

- polyvalent 2-nm gold nanoparticle-oligonucleotide conjugates. *J Am Chem Soc* 2008;**130**:5430–1.
163. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. *Angew Chemie - Int Ed* 2010;**49**:3280–94.
164. Patel PC, Giljohann DA, Daniel WL, Zheng D, Prigodich AE, Mirkin CA. Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. *Bioconjug Chem* 2010;**21**:2250–6.
165. Zani I, Stephen S, Mughal N, Russell D, Homer-Vanniasinkam S, Wheatcroft S, et al. Scavenger Receptor Structure and Function in Health and Disease. *Cells* 2015;**4**:178–201.
166. Zhang K, Hao L, Hurst SJ, Mirkin CA. Antibody-linked spherical nucleic acids for cellular targeting. *J Am Chem Soc* 2012;**134**:16488–91.
167. Hao L, Patel PC, Alhasan AH, Giljohann DA, Mirkin CA. Nucleic acid-gold nanoparticle conjugates as mimics of microRNA. *Small* 2011;**7**:3158–62.
168. Oishi M, Nakaogami J, Ishii T, Nagasaki Y. Smart PEGylated gold nanoparticles for the cytoplasmic delivery of siRNA to induce enhanced gene silencing. *Chem Lett* 2006;**35**:1046–7.
169. Giljohann DA, Seferos DS, Prigodich AE, Patel PC, Mirkin CA. Gene regulation with polyvalent siRNA-nanoparticle conjugates. *J Am Chem Soc* 2009;**131**:2072–3.
170. Zheng D, Giljohann DA, Chen DL, Massich MD, Wang XQ, Iordanov H, et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. *Proc Natl Acad Sci U S A* 2012;**109**:11975–80.
171. Massich MD, Giljohann DA, Seferos DS, Ludlow LE, Horvath CM, Mirkin CA. Regulating immune response using polyvalent nucleic acid-gold nanoparticle conjugates. *Mol Pharm* 2009;**6**:1934–40.
172. Cheung W, Pontoriero F, Taratula O, Chen AM, He H. DNA and carbon nanotubes as medicine. *Adv Drug Deliv Rev* 2010;**62**:633–49.
173. Qi L, Gao X. Quantum dot—amphipol nanocomplex for intracellular delivery and real-time imaging of siRNA. *ACS Nano* 2008;**2**:1403–10.
174. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics,

- therapies and toxicity. *Chem Soc Rev* 2009;**38**:1759–82.
175. Kim ST, Chompoosor A, Yeh YC, Agasti SS, Solfiell DJ, Rotello VM. Dendronized gold nanoparticles for siRNA delivery. *Small* 2012;**8**:3253–6.
176. Fitzgerald KA, Rahme K, Guo J, Holmes JD, O’Driscoll CM. Anisamide-targeted gold nanoparticles for siRNA delivery in prostate cancer—synthesis, physicochemical characterisation and *in vitro* evaluation. *J Mater Chem B* 2016;**4**:2242–52.
177. Ahwazi RP, Kiani M, Dinarvand M, Assali A, Tekie FSM, Dinarvand R, et al. Immobilization of HIV-1 TAT peptide on gold nanoparticles: a feasible approach for siRNA delivery. *J Cell Physiol* 2020;**235**:2049–59.
178. Shirazi AN, Paquin KL, Howlett NG, Mandal D, Parang K. Cyclic peptide-capped gold nanoparticles for enhanced siRNA delivery. *Molecules* 2014;**19**:13319–31.
179. Paul AM, Shi Y, Acharya D, Douglas JR, Cooley A, Anderson JF, et al. Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection *in vitro*. *J Gen Virol* 2014;**95**:1712–22.
180. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. *Nat Rev Genet* 2014;**15**:541–55.
181. Jensen SA, Day ES, Ko CH, Hurley LA, Luciano JP, Kouri FM, et al. Spherical nucleic acid nanoparticle conjugates as an RNAi-based therapy for glioblastoma. *Sci Transl Med* 2013;**5**:1–22.
182. Huang X, Hu Q, Braun GB, Pallaoro A, Morales DP, Zasadzinski J, et al. Light-activated RNA interference in human embryonic stem cells. *Biomaterials* 2015;**63**:70–9.
183. Jiang Y, Huo S, Hardie J, Liang XJ, Rotello VM. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. *Expert Opin Drug Deliv* 2016;**13**:547–59.
184. Elbakry A, Zaky A, Liebl R, Rachel R, Goepferich A, Breunig M. Layer-by-layer assembled gold nanoparticles for siRNA delivery. *Nano Lett* 2009;**9**:2059–64.
185. Lee SK, Han MS, Asokan S, Tung CH. Effective gene silencing by multilayered siRNA-coated gold nanoparticles. *Small* 2011;**7**:364–70.
186. Lee MY, Park SJ, Park K, Kim KS, Lee H, Hahn SK. Target-specific gene silencing of layer-by-

- layer assembled gold-cysteamine/siRNA/PEI/HA nanocomplex. *ACS Nano* 2011;**5**:6138–47.
187. Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and siRNA. *Front Pharmacol* 2014;**5**:1.26.
188. Falamarzian A, Xiong XB, Uludag H, Lavasanifar A. Polymeric micelles for siRNA delivery. *J Drug Deliv Sci Technol* 2012:43–54.
189. Fernandez AM, Van derpoorten K, Dasnois L, Lebtahi K, Dubois V, Lobl TJ, et al. *N*-Succinyl-( $\beta$ -alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute toxicity. *J Med Chem* 2001;**44**:3750–3.
190. Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. *Int J Pharm* 2013;**453**:198–214.
191. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. *J Control Release* 2000;**65**:271–84.
192. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. *Nanomedicine Nanotechnology, Biol Med* 2010;**6**:714–29.
193. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. *Drug Discov Today* 2006;**11**:812–8.
194. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci U S A* 1998;**95**:4607–12.
195. Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. *Trends Mol Med* 2015;**21**:223–32.
196. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. *J Control Release* 2010;**148**:135–46.
197. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. *Cancer Res* 2006;**66**:6732–40.
198. Jin C, Qian N, Zhao W, Yang W, Bai L, Wu H, et al. Improved therapeutic effect of DOX-

- PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')<sub>2</sub> for hepatocellular carcinoma. *Biomacromolecules* 2010;**11**:2422–31.
199. Cheng R, Meng F, Deng C, Klok HA, Zhong Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. *Biomaterials* 2013;**34**:3647–57. Doi: 10.1016/j.biomaterials.2013.01.084.
200. Liberti M V, Locasale JW. The Warburg effect: how does it benefit cancer cells?. *Trends Biochem Sci* 2016;**41**:211–8.
201. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor *versus* normal tissue: potential exploitation for the treatment of cancer. *Cancer Res* 1996;**56**:1194–8.
202. Yoshida T, Lai TC, Kwon GS, Sako K. PH-and ion-sensitive polymers for drug delivery. *Expert Opin Drug Deliv* 2013;**10**:1497–513.
203. Jiang B, Hom WL, Chen X, Yu P, Pavelka LC, Kisslinger K, et al. Magnetic Hydrogels from alkyne/cobalt carbonyl-functionalized ABA triblock copolymers. *J Am Chem Soc* 2016;**138**:4616–25.
204. Panja S, Dey G, Bharti R, Kumari K, Maiti TK, Mandal M, et al. Tailor-made temperature-sensitive micelle for targeted and on-demand release of anticancer drugs. *ACS Appl Mater Interfaces* 2016;**8**:12063–74.
205. Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellar nanomedicine for cancer therapy. *Exp Biol Med* 2009;**234**:123–31.
206. Duong HHP, Yung LYL. Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment. *Int J Pharm* 2013;**454**:486–95.
207. Christie RJ, Matsumoto Y, Miyata K, Nomoto T, Fukushima S, Osada K, et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. *ACS Nano* 2012;**6**:5174–89.
208. Lu HH, Huang CH, Shiue TY, Wang FS, Chang KK, Chen Y, et al. Erratum: highly efficient gene release in spatiotemporal precision approached by light and pH dual responsive copolymers. *Chem Sci* 2019;**10**:284–92.



209. Hao F, Lee RJ, Yang C, Zhong L, Sun Y, Dong S, et al. Targeted co-delivery of siRNA and methotrexate for tumor therapy *via* mixed micelles. *Pharmaceutics* 2019;**11**:1–19.
210. Hazekawa M, Nishinakagawa T, Kawakubo-Yasukochi T, Nakashima M. Glypican-3 gene silencing for ovarian cancer using siRNA-PLGA hybrid micelles in a murine peritoneal dissemination model. *J Pharmacol Sci* 2019;**139**:231–9.
211. Hao F, Dong S, Yang C, Li Z, Cheng Z, Zhong L, et al. Targeted and efficient delivery of siRNA using tunable polymeric hybrid micelles for tumor therapy. *Anticancer Res* 2019;**39**:1169–78.
212. Xu C, Li D, Cao Z, Xiong M, Yang X, Wang J. Facile hydrophobization of siRNA with anticancer drug for non-cationic nanocarrier-mediated systemic delivery. *Nano Lett* 2019;**19**:2688–93.
213. Wang X, Hhua Y, Xu G, Deng S, Yang D, Gao X. Targeting EZH2 for glioma therapy with a novel nanoparticle–siRNA complex. *Int J Nanomedicine* 2019;**14**:2637–53. 1.
214. Li G, Gao Y, Gong C, Han Z, Qiang L, Tai Z, et al. Dual-blockade immune checkpoint for breast cancer treatment based on a tumor-penetrating peptide assembling nanoparticle. *ACS Appl Mater Interfaces* 2019;**11**:39513–24
215. Yang Y, Meng Y, Ye J, Xia X, Wang H, Li L, et al. Sequential delivery of VEGF siRNA and paclitaxel for PVN destruction, anti-angiogenesis, and tumor cell apoptosis procedurally *via* a multi-functional polymer micelle. *J Control Release* 2018;**287**:103–20.
216. Suo A, Qian J, Xu M, Xu W, Zhang Y, Yao Y. Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA. *Mater Sci Eng C* 2017;**76**:659–72.
217. Lee SY, Yang CY, Peng CL, Wei MF, Chen KC, Yao CJ, et al. A theranostic micelleplex co-delivering Sn-38 and VEGF siRNA for colorectal cancer therapy. *Biomaterials* 2016;**86**:92–105.
218. Kanazawa T, Sugawara K, Tanaka K, Horiuchi S, Takashima Y, Okada H. Suppression of tumor growth by systemic delivery of anti-VEGF siRNA with cell-penetrating peptide-modified MPEG-PCL nanomicelles. *Eur J Pharm Biopharm* 2012;**81**:470–7.
219. Wu Y, Zhang Y, Zhang W, Sun C, Wu J, Tang J. Reversing of multidrug resistance breast cancer

- by co-delivery of P-gp siRNA and doxorubicin *via* folic acid-modified core-shell nanomicelles. *Colloids Surfaces B Biointerfaces* 2016;**138**:60–9.
220. Fang S, Wu L, Li M, Yi H, Gao G, Sheng Z, et al. ZEB1 knockdown mediated using polypeptide cationic micelles inhibits metastasis and effects sensitization to a chemotherapeutic drug for cancer therapy. *Nanoscale* 2014;**6**:10084–94.
221. Xiong XB, Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. *ACS Nano* 2011;**5**:5202–13.
222. Yu SS, Lau CM, Barham WJ, Onishko HM, Nelson CE, Li H, et al. Macrophage-specific RNA interference targeting *via* “click”, mannosylated polymeric micelles. *Mol Pharm* 2013;**10**:975–87.
223. Li Y, Ma J, Zhu H, Gao X, Dong H, Shi D. Green synthetic, multifunctional hybrid micelles with shell embedded magnetic nanoparticles for theranostic applications. *ACS Appl Mater Interfaces* 2013;**5**:7227–35.
224. Song N, Ding M, Pan Z, Li J, Zhou L, Tan H, et al. Construction of targeting-clickable and tumor-cleavable polyurethane nanomicelles for multifunctional intracellular drug delivery. *Biomacromolecules* 2013;**14**:4407–19.
225. Ding M, Song N, He X, Li J, Zhou L, Tan H, et al. Toward the next-generation nanomedicines: design of multifunctional multiblock polyurethanes for effective cancer treatment. *ACS Nano* 2013;**7**:1918–28.
226. Zhu L, Wang T, Perche F, Taigind A, Torchilin VP. Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. *Proc Natl Acad Sci U S A* 2013;**110**:17047–52. D
227. Tang X, Rao J, Yin S, Wei J, Xia C, Li M, et al. PD-L1 knockdown *via* hybrid micelle promotes paclitaxel induced cancer-immunity cycle for melanoma treatment. *Eur J Pharm Sci* 2019;**127**:161–74.
228. Pan J, Mendes LP, Yao M, Filipczak N, Garai S, Thakur GA, et al. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance. *Eur J Pharm Biopharm* 2019;**136**:18–28.

229. Kim SH, Jeong JH, Lee SH, Kim SW, Park TG. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. *J Control Release* 2008;**129**:107–16.
230. Decuzzi P, Ferrari M. The receptor-mediated endocytosis of nonspherical particles. *Biophys J* 2008;**94**:3790–7.
231. Xiong XB, Uludağ H, Lavasanifar A. Virus-mimetic polymeric micelles for targeted siRNA delivery. *Biomaterials* 2010;**31**:5886–93.
232. Rabideau AE, Pentelute BL. Delivery of non-native cargo into mammalian cells using anthrax lethal toxin. *ACS Chem Biol* 2016;**11**:1490–501.
233. Cheng L, Yang L, Meng F, Zhong Z. Protein nanotherapeutics as an emerging modality for cancer therapy. *Adv Healthc Mater* 2018;**7**:1–9.
234. Liu X, Wu F, Ji Y, Yin L. Recent advances in anti-cancer protein/peptide delivery. *Bioconjug Chem* 2019;**30**:305–24.
235. Stewart MP, Langer R, Jensen KF. Intracellular delivery by membrane disruption: mechanisms, strategies, and concepts. *Chem Rev* 2018;**118**:7409–531.
236. Yang J, Zhang Q, Chang H, Cheng Y. Surface-engineered dendrimers in gene delivery. *Chem Rev* 2015;**115**:5274–300.
237. Wang H, Miao W, Wang F, Cheng Y. A Self-assembled coumarin-anchored dendrimer for efficient gene delivery and light-responsive drug delivery. *Biomacromolecules* 2018;**19**:2194–201.
238. Liu H, Chang H, Lv J, Jiang C, Li Z, Wang F, et al. Screening of efficient siRNA carriers in a library of surface-engineered dendrimers. *Sci Rep* 2016;**6**:1–11.
239. Yang J, Hendricks W, Liu G, McCaffery JM, Kinzler KW, Huso DL, et al. A nanoparticle formulation that selectively transfects metastatic tumors in mice. *Proc Natl Acad Sci U S A* 2013;**110**:14717–22.
240. Hashim PK, Okuro K, Sasaki S, Hoashi Y, Aida T. Reductively cleavable nanocaplets for siRNA delivery by template-assisted oxidative polymerization. *J Am Chem Soc* 2015;**137**:15608–11.

241. Yang XZ, Du JZ, Dou S, Mao CQ, Long HY, Wang J. Sheddable ternary nanoparticles for tumor acidity-targeted siRNA delivery. *ACS Nano* 2012;**6**:771–81.
242. Bakker MH, Lee CC, Meijer EW, Dankers PYW, Albertazzi L. Multicomponent supramolecular polymers as a modular platform for intracellular delivery. *ACS Nano* 2016;**10**:1845–52.
243. Juanes M, Creese O, Fernández-Trillo P, Montenegro J. Messenger RNA delivery by hydrazone-activated polymers. *Medchemcomm* 2019;**10**:1138–44.
244. Spagnou S, Miller AD, Keller M. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. *Biochemistry* 2004;**43**:13348–56.
245. Moghimi SM, Symonds P, Murray JC, Hunter AC, Debska G, Szewczyk A. A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. *Mol Ther* 2005;**11**:990–5.
246. Namgung R, Kim J, Singha K, Kim CH, Kim WJ. Synergistic effect of low cytotoxic linear polyethylenimine and multiarm polyethylene glycol: study of physicochemical properties and *in vitro* gene transfection. *Mol Pharm* 2009;**6**:1826–35.
247. Mao S, Neu M, Germershaus O, Merkel O, Sitterberg J, Bakowsky U, et al. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. *Bioconjug Chem* 2006;**17**:1209–18.
248. Park IK, Singha K, Arote RB, Choi YJ, Kim WJ, Cho CS. pH-responsive polymers as gene carriers. *Macromol Rapid Commun* 2010;**31**:1122–33.
249. De las Heras Alarcón C, Pennadam S, Alexander C. Stimuli responsive polymers for biomedical applications. *Chem Soc Rev* 2005;**34**:276–85.
250. Oskuee RK, Philipp A, Dehshahri A, Wagner E, Ramezani M. The impact of carboxyalkylation of branched polyethylenimine on effectiveness in small interfering RNA delivery. *J Gene Med* 2010;**12**:729–38.
251. Hunter AC, Moghimi SM. Therapeutic synthetic polymers: a game of Russian roulette?. *Drug Discov Today* 2002;**7**:998–1001.

252. Philipp A, Zhao X, Tarcha P, Wagner E, Zintchenko A. Hydrophobically modified oligoethylenimines as highly efficient transfection agents for siRNA delivery. *Bioconjug Chem* 2009;**20**:2055–61.
253. Kim T il, Lee M, Kim SW. A guanidinylated bioreducible polymer with high nuclear localization ability for gene delivery systems. *Biomaterials* 2010;**31**:1798–804.
254. Son S, Singha K, Kim WJ. Bioreducible BPEI-SS-PEG-cNGR polymer as a tumor targeted nonviral gene carrier. *Biomaterials* 2010;**31**:6344–54.
255. Son S, Hwang DW, Singha K, Jeong JH, Park TG, Lee DS, et al. RVG peptide tethered bioreducible polyethylenimine for gene delivery to brain. *J Control Release* 2011;**155**:18–25.
256. Singha K, Namgung R, Kim WJ. Polymers in small-interfering RNA delivery. *Nucleic Acid Ther* 2011;**21**:133–47.
257. Kim WJ, Chang CW, Lee M, Kim SW. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy. *J Control Release* 2007;**118**:357–63.
258. Biswal BK, Debata NB, Verma RS. Development of a targeted siRNA delivery system using FOL–PEG–PEI conjugate. *Mol Biol Rep* 2010;**37**:2919–26.
259. Yamaoka T, Tabata Y, Ikada Y. Body distribution profile of polysaccharides after intravenous administration. *Drug Deliv* 1993;**1**:75–82.
260. Park IK, Ihm JE, Park YH, Choi YJ, Kim SI, Kim WJ, et al. Galactosylated chitosan (GC)-graft-poly(vinyl pyrrolidone) (PVP) as hepatocyte-targeting DNA carrier: preparation and physicochemical characterization of GC–graft–PVP/DNA complex (1). *J Control Release* 2003;**86**:349–59.
261. Kim SK, Park KM, Singha K, Kim J, Ahn Y, Kim K, et al. Galactosylated cucurbituril-inclusion polyplex for hepatocyte-targeted gene delivery. *Chem Commun* 2010;**46**:692–4.
262. Lee K, Bae KH, Lee Y, Lee SH, Ahn CH, Park TG. Pluronic/polyethylenimine shell crosslinked nanocapsules with embedded magnetite nanocrystals for magnetically triggered delivery of siRNA. *Macromol Biosci* 2010;**10**:239–45.
263. Yuan X, Li N, Rathinavelu A, Hao J, Narasimhan M, He M, et al. siRNA drug delivery by

- biodegradable polymeric nanoparticles. *J Nanosci Nanotechnol* 2006;**6**:2821–8.
264. Son S, Kim WJ. Biodegradable nanoparticles modified by branched polyethylenimine for plasmid DNA delivery. *Biomaterials* 2010;**31**:133–43.
265. Tahara K, Sakai T, Yamamoto H, Takeuchi H, Kawashima Y. Establishing chitosan coated PLGA nanosphere platform loaded with wide variety of nucleic acid by complexation with cationic compound for gene delivery. *Int J Pharm* 2008;**354**:210–6.
266. Cun D, Foged C, Yang M, Frøkjær S, Nielsen HM. Preparation and characterization of poly(D,L-lactide-*co*-glycolide) nanoparticles for siRNA delivery. *Int J Pharm* 2010;**390**:70–5.
267. Cun D, Jensen DK, Maltesen MJ, Bunker M, Whiteside P, Scurr D, et al. High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. *Eur J Pharm Biopharm* 2011;**77**:26–35.
268. Wang J, Feng SS, Wang S, Chen Z ying. Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. *Int J Pharm* 2010;**400**:194–200.
269. Hombach J, Bernkop-Schnürch A. Chitosan solutions and particles: evaluation of their permeation enhancing potential on MDCK cells used as blood brain barrier model. *Int J Pharm* 2009;**376**:104–9.
270. Andersen M, Lichawska A, Arpanaei A, Rask Jensen SM, Kaur H, Oupicky D, et al. Surface functionalisation of PLGA nanoparticles for gene silencing. *Biomaterials* 2010;**31**:5671–7.
271. Alshamsan A, Haddadi A, Hamdy S, Samuel J, El-Kadi AOS, Uludağ H, et al. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response. *Mol Pharm* 2010;**7**:1643–54.
272. Oster CG, Kissel T. Comparative study of DNA encapsulation into PLGA microparticles using modified double emulsion methods and spray drying techniques. *J Microencapsul* 2005;**22**:235–44.
273. Katas H, Cevher E, Alpar HO. Preparation of polyethyleneimine incorporated poly(D,L-lactide-*co*-glycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery. *Int J Pharm* 2009;**369**:144–54.

274. Risnayanti C, Jang YS, Lee J, Ahn HJ. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. *Sci Rep* 2018;**8**:1–12.
275. Patil Y, Panyam J. Polymeric nanoparticles for siRNA delivery and gene silencing. *Int J Pharm* 2009;**367**:195–203.
276. Hasan W, Chu K, Gullapalli A, Dunn SS, Enlow EM, Luft JC, et al. Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer. *Nano Lett* 2012;**12**:287–92.
277. Wang L, Griffel B, Xu X. Synthesis of PLGA–lipid hybrid nanoparticles for siRNA delivery using the emulsion method PLGA–PEG–lipid nanoparticles for siRNA delivery. *Methods Mol Biol* 2017;**1632**:231–40.
278. Mao S, Sun W, Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. *Adv Drug Deliv Rev* 2010;**62**:12–27.
279. Opanasopit P, Techaarpornkul S, Rojanarata T, Ngawhirunpat T, Ruktanonchai U. Nucleic acid delivery with chitosan hydroxybenzotriazole. *Oligonucleotides* 2010;**20**:127–36.
280. Rojanarata T, Opanasopit P, Techaarpornkul S, Ngawhirunpat T, Ruktanonchai U. Chitosan-thiamine pyrophosphate as a novel carrier for siRNA delivery. *Pharm Res* 2008;**25**:2807–14.
281. Roy K, Ghosn B, Kasturi S. Enhancing polysaccharide-mediated delivery of nucleic acids through functionalization with secondary and tertiary amines. *Curr Top Med Chem* 2008;**8**:331–40.
282. Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen M, et al. RNA interference *in vitro* and *in vivo* using a novel chitosan/siRNA nanoparticle system. *Mol Ther* 2006;**14**:476–84.
283. Choi B, Cui ZK, Kim S, Fan J, Wu BM, Lee M. Glutamine-chitosan modified calcium phosphate nanoparticles for efficient siRNA delivery and osteogenic differentiation. *J Mater Chem B* 2015;**3**:6448–55.
284. Ni S, Xie Y, Tang Y, Liu Y, Chen J, Zhu S. Nebulized anionic guanidinylated *O*-carboxymethyl chitosan/*N*-2-hydroxypropyltrimethyl ammonium chloride chitosan nanoparticles for siRNA

- pulmonary delivery: preparation, characterization and *in vitro* evaluation. *J Drug Target* 2017;**25**:451–62.
285. Sun P, Huang W, Jin M, Wang Q, Fan B, Kang L, et al. Chitosan-based nanoparticles for survivin targeted siRNA delivery in breast tumor therapy and preventing its metastasis. *Int J Nanomedicine* 2016;**11**:4931–45.
286. Shahana S, Kampf C, Roomans GM. Effects of the cationic protein poly-L-arginine on airway epithelial cells *in vitro*. *Mediators Inflamm* 2002;**11**:141–8.
287. Noh SM, Park MO, Shim G, Han SE, Lee HY, Huh JH, et al. Pegylated poly-L-arginine derivatives of chitosan for effective delivery of siRNA. *J Control Release* 2010;**145**:159–64.
288. Kim EJ, Shim G, Kim K, Kwon IC, Oh YK, Shim CK. Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs. *J Gene Med* 2009;**11**:791–803.
289. Plianwong S, Opanasopit P, Ngawhirunpat T, Rojanarata T. Chitosan combined with poly-L-arginine as efficient, safe, and serum-insensitive vehicle with RNase protection ability for siRNA delivery. *Biomed Res Int* 2013;**2013**:1–9.
290. Wan K, Li J, Li D, Ge J, Wang Y, Li X, et al. Novel hydroxybutyl chitosan nanoparticles for siRNA delivery targeting tissue factor inhibits proliferation and induces apoptosis in human vascular smooth muscle cells. *Mol Med Rep* 2015;**12**:7957–62.
291. Arami S, Rashidi MR, Mahdavi M, Fathi M, Entezami AA. Synthesis and characterization of Fe<sub>3</sub>O<sub>4</sub>-PEG-LAC-chitosan-PEI nanoparticle as a survivin siRNA delivery system. *Hum Exp Toxicol* 2017;**36**:227–37.
292. Shen W, Wang R, Fan Q, Gao X, Wang H, Shen Y, et al. Natural polyphenol inspired polycatechols for efficient siRNA delivery. *CCS Chem* 2020;**2**:146–57.
293. Chung JE, Tan S, Gao SJ, Yongvongsoontorn N, Kim SH, Lee JH, et al. Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy. *Nat Nanotechnol* 2014;**9**:907–12.
294. Shen W, Wang Q, Shen Y, Gao X, Li L, Yan Y, et al. Green tea catechin dramatically promotes RNAi mediated by low-molecular-weight polymers. *ACS Cent Sci* 2018;**4**:1326–33.



295. Hassler MR, Turanov AA, Alterman JF, Haraszti RA, Coles AH, Osborn MF, et al. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery *in vivo*. *Nucleic Acids Res* 2018;**46**:2185–96.
296. Mansoori B, Mohammadi A, Shir Jang S, Baradaran B. Mechanisms of immune system activation in mammals by small interfering RNA (siRNA). *Artif Cells, Nanomedicine Biotechnol* 2016;**44**:1589–96.
297. Huntzinger E, Izaurralde E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. *Nat Rev Genet* 2011;**12**:99–110.
298. Deleavey GF, Watts JK, Damha MJ. Chemical modification of siRNA. *Current Protocols in Nucleic Acid Chemistry*, 2009;**39**:1.
299. Allerson CR, Sioufi N, Jarres R, Prakash TP, Naik N, Berdeja A, et al. Fully 2'-modified oligonucleotide duplexes with improved *in vitro* potency and stability compared to unmodified small interfering RNA. *J Med Chem* 2005;**48**:901–4.
300. Shan G, Li Y, Zhang J, Li W, Szulwach KE, Duan R, et al. A small molecule enhances RNA interference and promotes microRNA processing. *Nat Biotechnol* 2008;**26**:933–40.
301. Diebold SS, Massacrier C, Akira S, Patrel C, Morel Y, Reis e Sousa C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. *Eur J Immunol* 2006;**36**:3256–67.
302. Wei P, Sun M, Yang B, Xiao J, Du J. Ultrasound-responsive polymersomes capable of endosomal escape for efficient cancer therapy. *J Control Release* 2020;**322**:81–94.
303. Puri A, Viard M, Zakrevsky P, Zampino S, Chen A, Isemann C, et al. Photoactivation of sulfonated polyplexes enables localized gene silencing by DsiRNA in breast cancer cells. *Nanomedicine Nanotechnology, Biol Med* 2020;**26**:102176.
304. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated *in vivo* delivery of small interfering RNAs *via* cell-surface receptors. *Nat Biotechnol* 2005;**23**:709–17.
305. Sarett SM, Werfel TA, Lee L, Jackson MA, Kilchrist K V, Brantley-Sieders D, et al. Lipophilic

- siRNA targets albumin *in situ* and promotes bioavailability, tumor penetration, and carrier-free gene silencing. *Proc Natl Acad Sci U S A* 2017;**114**:E6490–7.
306. Sato Y, Nakamura T, Yamada Y, Harashima H. Development of a multifunctional envelope-type nano device and its application to nanomedicine. *J Control Release* 2016;**244**:194–204.
307. Khalil IA, Kogure K, Futaki S, Hama S, Akita H, Ueno M, et al. Octaarginine-modified multifunctional envelope-type nanoparticles for gene delivery. *Gene Ther* 2007;**14**:682–9.
308. Moriguchi R, Kogure K, Akita H, Futaki S, Miyagishi M, Taira K, et al. A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids. *Int J Pharm* 2005;**301**:277–85.
309. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, et al. *in vivo* delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. *Nat Biotechnol* 2009;**27**:925–32.
310. Khalil IA, Kimura S, Sato Y, Harashima H. Synergism between a cell penetrating peptide and a pH-sensitive cationic lipid in efficient gene delivery based on double-coated nanoparticles. *J Control Release* 2018;**275**:107–16.
311. Rungta RL, Choi HB, Lin PJC, Ko RWY, Ashby D, Nair J, et al. Lipid nanoparticle delivery of sirna to silence neuronal gene expression in the brain. *Mol Ther - Nucleic Acids* 2013;**2**.
312. Chaudhary A, Garg S. siRNA delivery using polyelectrolyte-gold nanoassemblies in neuronal cells for *BACE1* gene silencing. *Mater Sci Eng C* 2017;**80**:18–28.
313. Solanki A, Shah S, Yin PT, Lee KB. Nanotopography-mediated reverse uptake for siRNA delivery into neural stem cells to enhance neuronal differentiation. *Sci Rep* 2013;**3**:1–7.
314. Kumar P, Wu H, McBride JL, Jung KE, Hee Kim M, Davidson BL, et al. Transvascular delivery of small interfering RNA to the central nervous system. *Nature* 2007;**448**:39–43.
315. Huwyler J, Drewe J, Krähenbühl S. Tumor targeting using liposomal antineoplastic drugs. *Int J Nanomedicine* 2008;**3**:21–9.
316. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. *Pharm Res* 2000;**17**:521–5.

317. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. *Adv Drug Deliv Rev* 2007;**59**:164–82.
318. Filion MC, Phillips NC. Major limitations in the use of cationic liposomes for DNA delivery. *Int J Pharm* 1998;**162**:159–70.
319. Sharma A, Madhunapantula S V, Robertson GP. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. *Expert Opin Drug Metab Toxicol* 2012;**8**:47–69.

**Table 1** Chemotherapy-based sensitization using siRNA.

siRNA	Target gene	Target protein	Target drug	Cancer	Observation	Ref.
Anti-MDR1 silencing RNA	<i>ABCB1</i>	P-gp 1 also known as MDR1	DOX or MTX	Cancer known to overexpress the MDR1 gene to develop drug resistance	siRNA downregulated MDR1 mRNA expression by 50% in breast carcinoma and osteosarcoma cell lines. It inhibited tumor cell proliferation up to 90% ( $P<0.01$ ), when co-administered with DOX or methotrexate, despite the known chemoresistance of the cell lines. siRNAs reduced the IC <sub>50</sub> of DOX and methotrexate by more than 10-fold ( $P<0.01$ )	14
EK-specific siRNA	<i>DEK</i> gene (involved in chromatin reconstruction )	DEK nuclear protein	Mitoxantrone or piroxicam carboplatin	TCC in canine	This study confirmed that DEK mRNA knock-down in canine TCC cell lines could inhibit proliferation, decrease cell viability, and enhance sensitivity.	15

					The outcome suggests that <i>DEK</i> inhibition may support cell survival and represent a valid target for novel therapeutics or combination therapies with classical anti-cancer drugs	
siRNA against survivin	Survivin ( <i>BIRC5</i> )	Survivin, also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5	Gemcitabine	Human pancreatic cancer cell lines of Panc-1 and BxPC3	It was observed that the suppression of survivin could enhance the chemosensitivity of pancreatic cancer cells to gemcitabine	16
Dual siRNA-mediated silencing of <i>Mcl-1</i> and Survivin in U-937 AML cells	Myeloid cell leukaemia-1 gene ( <i>MCL-1</i> ) and survivin ( <i>BIRC5</i> )	Myeloid cell leukaemia-1	Etoposide	U-937 AML cells	The results confirmed that <i>MCL-1</i> and survivin have a crucial role in cell survival and sensitivity of U-937 cells to etoposide	17
siRNA against RRM2	<i>RRM2</i> gene coding for the M2 subunit of ribonucleotide	Ribonucleotide reductase	Gemcitabine	Pancreatic ductal adenocarcinoma cell lines PANC1, MIAPaCa2, BxPC3,	Simultaneous action of <i>RRM2</i> silencing and gemcitabine resulted in suppressed proliferation, enhanced apoptosis	18

	reductase			and Capan2	and reduced metastasis. The RRM2 silencing induced gemcitabine chemoresistance in pancreatic adenocarcinoma	
siRNA against TS1058	<i>TYMS</i>	Thymidylate synthase	DOX	Human colon cancer RKO	TS1058 siRNAs were found to be effective inhibitors of TS expression and could chemosensitise colon cancer cells to DOX	19
siRNA against VEGF	<i>VEGFA</i>	VEGF	DOX	Hep3B cells	<i>VEGF</i> gene silencing was found to enhance the chemosensitivity of Hep3B cells towards DOX	20
RBFOX3-specific siRNA	<i>RBFOX3</i>	RNA binding protein, FOX-1 homolog	5-FU	Human hepatocellular carcinoma cells (SNU-449, Hep3B, Bel-7402, SNU-387, and HepG2) and human immortalized hepatic cell line MIHA	<i>RBFOX3</i> gene silencing induced the cell apoptosis, inhibited migration and invasion mediated by 5-FU	21
siRNA against	<i>SRC</i>	c-Src tyrosine kinase also known as proto-oncogene	Gemcitabine	PANC1, MIAPaCa2, BxPC3, and Capan2	c-Src played a crucial role in pancreatic adenocarcinoma	22

c-Src		tyrosine-protein kinase Src		pancreatic adenocarcinoma cell lines	chemoresistance and could be a possible target for therapeutic agents	
EGFR siRNA	<i>EGFR</i>	Epidermal growth factor receptor	Cisplatin, 5-FU, and docetaxel	Human head and neck squamous carcinoma cell lines HSC-2 (JCRB0622) and SAS (JCRB0260)	<i>EGFR</i> gene silencing in combination with cisplatin, 5-FU, and docetaxel increased chemosensitivity of all the drugs with an increase in apoptosis	23
siRNA targeting stathmin	<i>STMN1</i>	Stathmin, also known as metastasin and oncoprotein 18	Taxanes	Human osteosarcoma cell lines (Saos-2 and MG63)	Stathmin downregulation along with Taxanes showed potent anti-cancer activity in human osteosarcomas	24
DR1-targeting siRNA (siMDR1)	<i>MDR1</i>	MDR1	PTX	Human colon cancer cell line HT-29	<i>MDR1</i> gene silencing significantly reduced the MDR1 expression in human colon CSCs, and enhanced chemosensitivity to PTX	25
Survivin-targeted siRNA	<i>Survivin (BIRC5)</i>	Survivin, also called baculoviral inhibitor of apoptosis repeat-containing 5	Chemosensitivity	Androgen-independent prostate cancer cell lines PC-3, PC-3M, and DU145, and	Silencing of survivin by RNAi inhibited cell proliferation and enhanced chemosensitivity of	26

		or BIRC5		androgen-dependent prostate cancer cell lines LNCaP and 22RV1	prostate cancer cells	
Bmi1 siRNA	<i>BMI1</i>	Polycomb complex protein BMI-1	Cisplatin	Human endometrial cancer cell line HEC1A and Ishikawa cell lines	Dual treatment with cisplatin and <i>BMI1</i> silencing resulted in a synergistic anti-cancer effect, which was higher than that was shown by cisplatin alone	27
SaOS -2/NRP-1-siRNA	<i>NRP1</i>	NRP-1	DOX	Human osteosarcoma cell SaOS-2	<i>NRP-1</i> gene silencing significantly enhanced chemosensitivity to DOX	28
siRNAs targeting Girdin	<i>CCDC88A</i>	Girdin	Oxaliplatin	CACO-2, D2, DLD1, HCT15, HCT116, HUTU80, SW48, SW480, SW620, SW837, CX-1, COLO205, GP2D, GP5D, HCT15, LS174T and LS180	Girdin silencing enhances chemosensitivity of colorectal cancer cells to oxaliplatin <i>via</i> TOP2B down-regulation	29



siRNAs targeting RRM2	<i>RRM2</i> Gene which codes for the M2 subunit of ribonucleotide reductase	Ribonucleotide reductase	DOX	PANC-1, a pancreatic carcinoma cell line, HEK293A, a human embryonic kidney cell line	SiRRM2 was found to significantly inhibit pancreatic tumor growth alone or in combinations with DOX	30
SiRNA against HIF-1 $\alpha$	<i>HIF1A</i>	HIF-1 $\alpha$	Gemcitabine	MIA PaCa-2 cells	The HIF-1 $\alpha$ silencing resulted in decreased cell proliferation and enhanced chemosensitivity towards gemcitabine	31
DNMT1 siRNA	<i>DNMT</i>	DNA methyl transferase	Taxol	Human brain cell line GOS-3 (grade II/III oligo-dendroglioma, DMSZ, Germany) and U87-MG (grade IV glioblastoma)	siRNA mediated silencing followed by Taxol after 48 h or a combination of siRNA followed by TMZ after 24 h was found to be an effective glioma therapy	32
siRNA against TRK	<i>NTRK1</i>	TrkA	PTX	Human breast cancer cell line MCF-7	Results indicate that TrkA signalling plays a vital role in breast cancer chemo-resistance and metastasis. TrkA is an important therapeutic target	33

SiRNA against TGF- $\beta$ 1	<i>TGFB1</i>	TGF- $\beta$ 1	Temozolomide	SKOV3 cells	Results indicate that TGF- $\beta$ 1 silencing inhibits cancer cell growth and enhances chemosensitivity by induction of BRCA1/Smad3 signaling.	34
Plk-1-specific siRNA	<i>PLK1</i>	PLK-1	Gemcitabine	Human pancreatic adenocarcinoma cell lines AsPC-1, PANC1, and BxPC3, and the normal pancreas cell line HPDE6c7	Dual action of <i>Plk-1</i> silencing and gemcitabine chemotherapy has synergistic anti-cancer activity against pancreatic carcinoma	35
NRF2-siRNA	<i>NFE2L2</i>	Nuclear factor erythroid 2-related factor 2 (NRF2)	DOX, cisplatin, and sorafenib	Human osteosarcoma cell lines 143B (CRL-8303) and MG63 (CRL-1543)	Recombinant <i>NRF2</i> -siRNA was effective to sensitize both 143B and MG63 cells to DOX, cisplatin, and sorafenib, which was associated with significant downregulation of NRF2-targeted ATP-binding cassette (ABC) efflux transporters (ABCC3, ABCC4, and ABCG2)	36
Survivin siRNA	Survivin	Survivin, also	Cisplatin	HepG2 and	Suppression of survivin	37

	( <i>BIRC5</i> )	called baculoviral inhibitor of apoptosis repeat-containing 5 or <i>BIRC5</i>		SMMC-7721 hepatocellular carcinoma cells	expression by RNAi attenuated the malignant phenotype of hepatocellular carcinoma cells. Cells also showed decreased proliferation, increased apoptosis, and caspase-3 activity, and increased chemosensitivity to cisplatin	
AQP-5 siRNA	<i>AQP5</i>	AQP-5	DOX	DOX Resistant breast cancer cell line MCF-7 (MCF-7/ADR)	Inhibition of AQP-5 expression may reverse the drug resistance and enhance the chemosensitivity of breast cancer cells	38
Survivin siRNA	Survivin ( <i>BIRC5</i> )	Survivin, also called baculoviral inhibitor of apoptosis repeat-containing 5 or <i>BIRC5</i>	Cisplatin	Human pancreatic carcinoma cell line Panc-1	The knock-down of the survivin gene expression in Panc-1 cells effectively induced apoptosis with the simultaneous increase in the cisplatin sensitivity	39
Micelle/siRNA against ABCB1 complex	<i>ABCB1</i>	P-gp 1 also known as MDR1	DOX	CF-7/ADR cell lines	siRNA and DOX-loaded micelles were found to induce apoptosis and inhibit the growth of MDR tumors	40

siRNAs against survivin	Survivin ( <i>BIRC5</i> )	Survivin, also called baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5	PTX	MDR lung cancer cell line (H460/cDDP)	siRNA targeting survivin has the potential to enhance the sensitivity of drug-resistant lung cancer cells to paclitaxel	41
siRNA for DPYD or TYMS	<i>DPYD</i> and <i>TYMS</i>	Dihydropyrimidine dehydrogenase, thymidylate synthase	5-FU	Urothelial carcinoma	Thymidylate synthase was found to play an essential role in the prognosis of upper tract urothelial carcinoma, and siRNA may be a principal-agent for urothelial carcinoma treatment	42

**Table 2** Recent application of LPD for gene therapy.

Formulation	Composition	Target Gene	siRNA/Drug	Remark	Ref.
Cationic liposome– polycation–DNA and anionic liposome– polycation–DNA	Guanidinium-containing cationic lipid, <i>i.e.</i> , <i>N,N</i> -distearyl- <i>N</i> -methyl- <i>N</i> -2-( <i>N'</i> -arginyl) aminoethyl ammonium chloride, DOPA, 1,2-dioleoyl- <i>sn</i> -glycero-3-phosphoethanolamine, cholesterol, protamine sulfate (fraction X from salmon) and calf thymus DNA	<i>MDR</i> transporter	DOX and siRNA against MDR tumors	Enhanced DOX uptake was noted when VEGF siRNA (in LPD-I nanoparticles) and c-Myc siRNA (LPD-II nanoparticles) combined in nanoparticles. LPD-I, which was made up of DSAA has	124

				shown more toxicity than LPD-II	
Lipid-polycation-DNA nanoparticles containing DOTAP and targeted with PEG conjugated with anisamide	Non-glycerol-based cationic lipid which includes guanidinium and a lysine residue as the cationic headgroup (DSGLA); two liposome formulation were prepared, one with DSGLA and other with DOTAP	<i>EGFR</i> of H460 tumor cells	EGFR siRNA	LPD-PEG-AA developed with DSGLA delivered siRNA to the H460 cells. Although the siRNA delivered by LPD-PEG-AA containing either DOTAP or DSGLA could silence EGFR expression, a synergistic cell killing was only observed with DSGLA. The formulation containing DSGLA could induce more cellular apoptosis	124
PEGylated $17\beta$ -HSD1-siRNA/LPD	$17\beta$ -HSD1-siRNA modified with RGD peptide, 1,2-dioleoyl-3-trimethylammonium-propane, CHOL, distearoylphosphatidylethanolaminepoly(ethylene glycol) and calf thymus DNA	<i>HSD17B1</i>	$17\beta$ -HSD1-siRNA	Significant suppression of tumor growth in $17\beta$ -HSD1-siRNA/LPD-treated group when <i>HSD17B1</i> gene expression was knocked down. The untreated group has not	125

Targeted LPD-shRNA delivery system	shRNA-luc/protamine complexes coated with cationic liposomes consisting of DOTAP and cholesterol. PEGylated lipid (DSPE-PEG5000) was introduced post-production of nanoparticles	Gene for brachyury protein	shRNA	shown significant growth inhibition	The transfection efficiency of LPD-shRNA was higher than naked shRNA. shRNA delivered by LPD inhibited brachyury expression, enhanced apoptosis and downregulated mesenchymal biomarker and suppressed cell proliferation	126
LPD nanoparticles of multi-epitope peptides developed from the rat HER2/neu (rHER2/neu) oncogene	LPD NPs, including DOTAP/CHOL liposomes, protamine, and CpG oligonucleotides	Peptides produced from rat HER2/neu (rHER2/neu) oncogene to induce IFn- $\gamma$ and CTL responses	Multi-epitope peptides from the rat HER2/neu (rHER2/neu) oncogene	Results demonstrate that rHER2/neu-peptides (p5 and p435) and their encapsulation can induce an antigen-specific immunity . This study also presented the first attempt to evaluate the effectiveness of natural rHER2/neu-peptides containing CTL	127	

				multi-epitope and encapsulated in LPD NPs	
Lipid-polycation-hyaluronic acid	Polymer metformin, Hyaluronic acid (for condensation), cationic 1,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP) for liposome. DOTAP/CHOL (1:1, mol/mol) cationic liposome	VEGF siRNA for human lung cancer xenograft	VEGF siRNA, metformin	PolyMet successfully combined the intrinsic anti-cancer efficacy of metformin with the capacity to carry siRNA to enhance the therapeutic activity of anti-cancer gene therapy	128
Targeted LPD conjugated with anti-EGFR antibody	DOTAP (chloride salt), CHOL, DSPE-mPEG and DSPE-PEG-Mal	<i>EGFR</i> in breast cancer cell lines MDA-MB-231, SK-BR3 and MCF-7	siRNA	The <i>in-vivo</i> accumulation of targeted LPD was higher than that of non-targeted LPD in MDA-MB-231 tumor 24 h post intravenous injection.	129

---

**Table 3** Passive and active micelles targeting.

Passive targeting of the micelles	Active targeting of the micelles	Ref.
Depends on the permeability of the rapidly forming vasculature. Pathological conditions like inflammation support permeation of micelles into the solid tumors	Depends on the ligands linked to the micelles and the expression of the receptor proteins on the cancer cells. Accumulation is supported by pathological conditions like inflammation	192
Accumulation inside the tumor preferably depends on the EPR effect	Accumulation inside the cells depends on the targeting ligand, receptor protein interaction, abundance of the receptor protein and EPR	193
Passive targeting <i>via</i> micelles takes advantage of the poorly developed vasculature. Vasculature with large fenestrations form to keep in pace with higher demand of the nutrients and oxygen, which leaves the endothelial cells poorly aligned with a large opening between them	Tumor cells for survival express several proteins at a higher quantity than the normal cells. This feature allows selective accumulation of such micelles	194
No need to modify the surface of the micelle with the targeting agent. PEGylation is required to reduce rapid excretion and enhance stability	Polymeric micelles can be functionalized for active targeting by chemically modifying their surface with targeting ligands that show a strong specificity for antigens or receptors over-expressed on cancer cells	195
Preferential binding to the cancer cell is not required. PEGylation helps it to accumulate in the tumor <i>via</i> enhancing	Actively targeted polymeric micelles decrease side-effects of drugs by allowing preferential accumulation in diseased cells and	196



EPF effect	facilitate cellular uptake by receptor-mediated endocytosis	
Does not guarantee the safe delivery of the DNA or siRNA to the cancer cells	Benefits the intracellular delivery of macromolecules like DNA, siRNA, and proteins	197
NA	Commonly used targeting, such as ligands including antibodies and their fragments, proteins, small molecules, peptides, aptamers, and sugar molecules	198

**Table 4** Stimuli responsive siRNA delivery system.

pH-Sensitive	Redox sensitive	Enzyme-sensitive micelles	Ultrasound	Magnetic field	Temperature-sensitive	Light-sensitive micelles
Drug delivery from micelles depends upon the pH the tumor	Drug delivery from micelles depends upon the change in the redox potential of the tumor microenvironment	Drug delivery from micelles depends upon altered expression of certain enzymes in	Drug delivery from micelles relies on the application of the	Drug delivery from micelles depends upon the application of the external magnetic	Drug delivery from micelles depends on the effects of the temperature on the heat-sensitive polymers	Drug delivery from the micelles depends on the UV-Visible or NIR light to

		cancerous cells	high-pressure wave of a frequency of 20 kHz	field		trigger drug release
The pH of the tumor is 6.5 due to high lactic acid production, whereas the pH of the healthy tissues is around 7.4. <sup>200</sup> The pH of the internal cellular organelles drops between 4 to 6, depending upon the organelles. <sup>201</sup>	Cancer cells have higher redox potential (100–1000 fold higher) as compared to the outside of the cells	Polymers used to make these micelles has the groups which are recognized by the enzyme or by the products of the enzymatic reaction causing morphological changes or destruction of the micelles	Ultrasound frequencies in the range of 20–100 kHz can penetrate deep inside the body tissue crossing the various body fluids.	Such micelles are composed of paramagnetic responsive materials like Fe <sub>3</sub> O <sub>4</sub> or Fe <sub>2</sub> O <sub>3</sub> . These materials respond to the externally applied magnetic field.	These micelles composed of the heat-responsive polymeric block, which upon exposure to the different temperatures, undergoes the phase change. Hydrophilic to hydrophobic changes are more common.	In these micelles, light-sensitive groups are included inside the block polymers, in the core, or on the shell. Generally, photosensitive groups or chromophores undergo the stereochemical conversion, <i>e.g.</i> , <i>cis</i> to <i>trans</i> conversion or <i>vice versa</i>
These pH-gradients have been exploited successfully to design	Higher intracellular redox potential is due to the high	These micelles could hold drugs in	Such micelles could hold the	These micelles hold the drugs in	These micelles hold the drugs at one phase of	These micelles carry the drugs in

pH-sensitive polymeric micelles which can release their therapeutic payloads when they encounter a change in the pH of their microenvironment	concentration of the glutathione tripeptide ( $\gamma$ -glutamyl-cysteinyl-glycine). Polymeric micelles designed using the disulfide linkage, which could hold the drug at its core under normal redox potential, but release it upon destabilization of disulphite bridge in higher redox potential.	the absence of enzymes or enzymatic products. The most common enzymes exploited for such release are the proteases, lipases, and glycosidases, including the enzyme engaged in glycolysis, angiogenesis, fatty acid synthesis, and matrix metalloproteinase.	drugs in the absence of ultrasonic wave stimulus but release it when they are disturbed upon exposure to the low-frequency ultrasonic waves	the absence of the externally applied magnetic field but release it upon destruction by externally applied magnetic field.	the polymeric block but release it upon phase change after exposure to the temperature change	one confirmation of the photosensitive materials but release it after conversion to its alternate form upon exposure to the light source
Most commonly used pH-sensitive polymers <sup>202</sup> are acrylic acid, methacrylic acid, propionic acid, 2-acrylamido-2-methylpropylsulfonic acid,	The basic principle of redox-responsive polymeric drug delivery systems is to utilize the differences in redox potentials between tumors	Azobenzene linkage is established at the copolymer junction of an amphiphilic diblock copolymer. Treatment with the	The most common copolymers used in acoustically activated drug	Jiang et al. <sup>203</sup> prepared a series of alkyne functionalized PPES- <i>b</i> -PEO- <i>b</i> -PES triblock	The most commonly used polymers to make thermosensitive micelles are PE-PCL- <i>b</i> -PNIPAM and PE-PCL- <i>b</i> -PNVCL <sup>204</sup>	The most commonly used photosensitive materials are the azobenzenes and their derivatives.

<p>2-methacryloxyethylsulfonic acid,  3-methacryloxy-2-hydroxypropylsulfonic acid,  ethylenesulfonic acid,  sulfoxyethyl methacrylate  hyaluronic acid, alginic acid,  acrylamide, aminoethyl methacrylate, polylysine,  polyhistidine, chitosan, etc.</p>	<p>and normal tissues. It has been demonstrated that GSH/glutathione disulfide is the most abundant redox couple in animal cells. In the cytosol and nuclei, the concentration of GSH reaches 10, while outside the cell, the concentration drops to about 2–20 mmol/L. The tumor has 4-fold higher GSH concentrations than that of healthy tissue. Disulfide linkages have been applied broadly in reduction-responsive polymeric drug delivery systems<sup>187</sup></p>	<p>enzyme azoreductase, in the presence of coenzyme NADPH, results in the cleavage of the azo-based copolymer junction, which disrupts the micellar assembly</p>	<p>delivery belong to the Pluronic family of triblock copolymers, <i>e.g.</i>, P105, F127, P85, L61, etc.</p>	<p>copolymers by RAFT polymerization and introduced cobalt by the reaction of the alkyne functionalities with Co<sub>2</sub>(CO)<sub>8</sub>. The metallated copolymers were cross-linked and formed magnetic cobalt nanoparticles after heating at 120 °C</p>	<p>Other examples of the light-sensitive materials include 11 <i>O</i>-nitrobenzyl esters, coumarinyl esters and spiropyrans spirooxazines</p>
--	--	--	---	--	--

**Table 5** Multifunctional micelles delivery of siRNA to cancer cells.

Function	Block polymer	Targeted/non-targeted	Cancer type	Ref.
Micelles combined DOX and PTX delivery	PLGA-PEG	Yes: TAT peptide (cell-penetrating peptide )	Human carcinoma KB cell line	206
Polymeric micelles for siRNA (siRNAs against <i>VEGF</i> ) delivery through the bloodstream to tumor models in mice	PEG- <i>b</i> -PLL	Yes: cyclo-arginine–glycine–glutamic acid (cRGD) peptide	H2BGFP-HeLa cells mice model	207
Micelles for anti-VEGF siRNA delivery	MPEG/PCL diblock copolymer	Yes: TAT peptide (cell penetrating peptide)	S-180 sarcoma cells	218
Polymeric micelles for macrophage-specific siRNA delivery	Oly(BMA- <i>co</i> -PAA- <i>co</i> -DMAEMA)- <i>b</i> -poly-(DMAEMA)- <i>b</i> -poly(AzEMA) triblock copolymer	Yes: mannosylated to achieve CD206 (mannose receptor)-targeted siRNA deliver	Immortalized human macrophages (THP-1) or human breast cancer cell lines (MDA-MB-231 and MDA-MB-468)	222
Multifunctional hybrid micelles with shell embedded magnetic nanoparticles for theranostic applications (magnetic oxide and	Pluronic F127 and peptide-amphiphile(PA) pal-AAAAHHHD	Controlled drug release using magnetic field stimuli	HeLa cells	223

oxorubicin)

Tumor-cleavable nanomicelles (DOX)	Polyurethane was synthesized from biodegradable PCL and LDI	Yes: folic acid	L929 and HeLa cells	224
Multi-functional multiblock polyurethane micelles (PTX)	PDO and PCL-bearing pH-responsive hydrazone bonds	pH-sensitive drug release	3T3 mouse fibroblasts and A431 cells and A431 tumor-bearing mice	225
MMP2-sensitive PTX-containing micellar	Self-assembling PEG2000-peptide-PTX conjugate, which contains the MMP2-cleavable octapeptide between PEG and PTX	Yes: TAT peptide (cell-penetrating peptide)	NSCLC xenograft mouse model	226
Hybrid micelle for co-delivery of PD-L1 siRNA and paclitaxel	98% PCL-PEG and 2% PCL-PEI	Non targeted	B16F10 or DC2.4 cells and B16F10 melanoma tumor-bearing mice (C57BL/6)	227
Micelles for the combination therapy with siRNA (siMDR-1) and chemotherapeutics (DOX)	4-Polyamidoamine conjugated with PEG-phospholipid	A2780 ADR, MCF7 ADR and MCF7	MDR cancer cells: human ovarian carcinoma (A2780 ADR) and breast cancer (MCF7 ADR)	228
Light and pH dual sensitive micelles for siRNA delivery	Light and pH-sensitive triblock copolymer of PEG- <i>b</i> -PDMAEMA- <i>b</i> -PPy	Light and pH-sensitive micelles	MDA-MB-231 cells	208

Micelles for the co-delivery of MTX and survivin siRNA	Polyethlenimine and mPEG	Yes: linolenic acid	HeLa cells	209
Hybrid micelles for glypican-3 siRNA	PLGA-PDPH (3-(2-pyridyldithio) propionyl hydrazide)	No	OV2944-HM-1 cells (HM-1), derived from the C57BL/6×C3H/HeNF1 (B6C3F1) mouse	210
Tunable polymeric hybrid micelles to deliver survivine siRNA	PEI and mPEG amphiphilic polymers (PEI-LA and mPEG-LA)	Linolic acid linked amphiphilic polymers	A549 cells	211
Facile hydrophobization micelles for siRNA (Plk1 siRNA) delivery	PEG- <i>b</i> -PLA micelles	No	DA-MB-231 cells	212
Micelles for EZH2 siRNA delivery	MPEG-PCL and DOTAP	Micelles protected siRNA delivery	U87 cells and GL261	213
Duel function targeted micelles for programmed cell death ligand 1 (PD-L1) small interfering RNA (siRNA) delivery and indoleamine	Cholesterol conjugated cell-penetrating peptide lin TT1 (Chol-HHHHHHHH-AKRGARST)	Yes: cell-penetrating peptide conjugated	4T1 cells and 4T1 mouse breast cancer allograft tumor model	214


2,3-dioxygenase inhibitor

Multi-functional polymer micelle for the sequential delivery of VEGF siRNA and paclitaxel	Triblock copolymer of PCL-PEG-PHIS	Yes: folate conjugated	MCF-7 cells and HUVEC cells and MCF-7 tumor-bearing female nude mice	215
pH/Reduction dual-responsive micelles for targeted intracellular co-delivery of DOX and Bcl-2 siRNA	PEGylated cationic triblock copolymer of PAH- <i>b</i> -PDMAPMA- <i>b</i> -PAH	Yes: folate conjugated	MCF-7 cells	216
Micelles as nanocarriers for 7-ethyl-10-hydroxycamptothecin, USPIO, and siRNA against <i>VEGF</i>	PDMA- <i>b</i> -PCL	No	Human colon adenocarcinoma cell line LS174T and LS174T grafted mice model	217s
Micelles for co-delivery of P-gp siRNA and DOX	Triblock polymers of PEG- <i>b</i> -(PCL- <i>g</i> -PEI)- <i>b</i> -PCL	Yes: folic acid conjugated	MCF-7 and MCF-7/ADR cells and tumor-bearing mice	219




Multifunctional polymeric micelles for the co-delivery of <i>ZEB1</i> siRNA and DOX	Copolymer: PEG-PLL-PLLeu	No	H460 cells and subcutaneous H460 mice model	220
Multifunctional Polymeric Micelles P-gp siRNA and DOX	$\beta$ -Cyclodextrin-poly-ethyl-enimine	No	MCF-7 and MCF-7/ADR cel	40
Multifunctional micellar nanocarriers for targeted co-delivery of MDR-1 siRNA and DOX	PEO- <i>b</i> -PCL	Integrin $\alpha v \beta 3$ -specific ligand (RGD4C) for active cancer targeting and the cell-penetrating peptide TAT for membrane activity	The P-gp overexpressing human melanoma cell line MDA-MB-435/LCC6MDR1 and female athymic nude mice (NCRNU-F) model of the MDA-MB-435/LCC6MDR1 cells	221


---



**Figure 1** Steps in RISC formation and function. Reprinted with the permission from Ref. 4. Copyright © 2012 ACS Publications.



**Figure 2** Schematic representation of the elaboration of the transferrin targeted pDNA- or siRNA-CDP nanoparticles (RONDEL). Reprinted with the permission from Ref. 93. Copyright © 2011 Royal Society of Chemistry



**Figure 3** The formation process of liposome/phosphate/calcium (LPC) nanoparticles. Reprinted with the permission from Ref. 131. Copyright © 2010 Taylor & Francis Group.